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Abstract
Proton magnetic resonance spectroscopy (MRS) non-invasively measures regional human
brain chemistry in vivo, providing concentration estimates for several metabolites in a
pre-selected region of interest. MRS has been applied to investigations of disease-related
metabolic and neurochemical alterations in schizophrenia since the early 90’s.
The objective of this research is to implement a metabolite-selective MRS method to
quantify endogenous concentrations of human brain serine. Serine is a naturally-occurring
amino acid and an important co-modulator of the N-Methyl D-aspartic Acid (NMDA)
glutamate receptor. Glutamate abnormalities have been implicated in the pathophysiology
of schizophrenia, especially its so-called negative and cognitive symptoms, which can be
relieved by D-serine supplements.
Measurements of serine have been impossible using standard MRS due to its low
concentration and strongly coupled spins. In this thesis, we implement and test an
advanced MRS pulse sequence, called DANTE-PRESS, using a narrow band
radiofrequency (RF) pulse to isolate the serine signals from the human brain spectra for
the first time on a 3.0 Tesla clinical scanner.
Test-retest reliability of in vitro serine measurements in brain-mimicking samples was
verified using ten repeated acquisitions from two serine samples with concentrations of
0.732 mM (similar to “in vivo”) and 1.464 mM (“double in vivo”) at baseline and one
week later. Within- and between-session reproducibility was measured with the
coefficient of variation (CV) and one-way ANOVA, respectively. Average serine “in
vivo” concentration at baseline, one week later, “double in vivo” at baseline, and one
week later were 1.13 ± 0.09 (CV = 8.3%), 1.06 ± 0.10 (CV = 9.9%), 2.18 ± 0.13 (CV =
5.7%) and 2.23 ± 0.14 (CV = 6.5%), respectively.
The thesis also presents the first 3.0 Tesla application of DANTE-PRESS in a human
brain region relevant to schizophrenia as proof-of-concept. Future studies can extend the
work to implementation of DANTE-PRESS at 7.0 Tesla and in vivo test-retest.
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Chapter 1

1.1

Introduction

The goal of this thesis is to describe the implementation of a novel proton magnetic
resonance spectroscopy (1H-MRS) technique in order to measure the in vivo
concentration of human brain serine. Detection of endogenous levels of serine has been
impossible with standard proton MRS and no existing technique can assess in vivo brain
serine levels on a clinical scanner of 3.0 Tesla (T) or less. The main objective of the thesis
is to implement a customized 1H-MRS technique on a clinical scanner of 3.0 T and
evaluate its test-retest reliability in phantoms. The secondary objective is to apply the
metabolite-selective MRS technique developed to detect the endogenous concentration of
serine in the human brain as an in vivo proof-of-concept. Precise and reliable
measurements of endogenous serine in the human brain using a customized 1H-MRS may
provide crucial information for research in neuro-psychiatric disorders particularly in
patients living with schizophrenia. The following chapter will introduce background
information, a brief history and description of schizophrenia, and the main motivation for
the development of human brain serine measurements. This chapter will review the
literature peripheral to administration of D-serine in patients with schizophrenia as an
adjuvant to standard treatment.

1.1.1 Schizophrenia
In 1896, German psychiatrist Emil Kraepelin introduced the concept of dementia praecox,
which is now known as schizophrenia.1 He also differentiated the unitary concept of
psychosis into two distinct categories on the basis of their etiology and clinical courses:
manic depression and dementia praecox. Subjects who were diagnosed with dementia
praecox were described as experiencing positive and negative symptoms (augmented or
diminished experiences), including hallucinations and disturbances in behaviour. He
significantly contributed to the understanding of psychotic disorders; some of his original

2

ideas have endured to this day and are comparable to the classification of schizophrenia in
the current Diagnostic and Statistical Manual of Mental Disorders, fifth Edition (DSM-5)
2

diagnostic classification psychiatric disorders. In the early twentieth century the

introduction of the term “schizophrenia” was first discussed by a Swiss psychiatrist
named Eugene Bleuler.3
Schizophrenia is a severe mental condition with a high morbidity and mortality rate,
which is described as a neuro-developmental brain disorder.4 It currently affects
approximately 1% of the global population and patients occupy approximately 40% of
psychiatric hospital beds.5, 6 The onset of symptoms is typically in late adolescence or
young adulthood, 7 and often results in lifetime treatment and therapy with antipsychotic
medications. Among the symptoms of this disease, neurocognitive and negative deficits
are the most prominent, affecting 40-80% of patients in clinical samples.8 Cognitive and
negative symptoms account for long term functional impairments. The efficacy of current
medications is limited in alleviating these deficits.9 Studies have shown that the economic
burden caused by schizophrenia remains high in Canada mainly due to the loss of
productivity as a result of morbidity.10, 11 The global cost of this illness on health care
budgets is significant; on average it amounts to about 1.5 to 3 percent of total national
health care expenses.11 Currently, there is no cure for schizophrenia, although it is a
disorder that is responsive to treatment. Thus, this severe mental disorder is worthy of
academic investigation; it is crucial to advance our understanding of the pathophysiology
of the disease to maximize our ability to treat schizophrenia.
Numerous reports have investigated the role of genetics or environmental factors in
schizophrenia. Studies indicate that environmental stressors including birth complications,
12

infections, 13 socioeconomic factors, or childhood adversity 14 may make a person more

susceptible to developing schizophrenia later in life. Studies of the familial risks and
heritability of schizophrenia have indicated that higher levels of risk for schizophrenia
exist among relatives.15 Adoption reports have illustrated that the risk for developing
schizophrenia was higher among biologic offspring even when they were adopted by
parents who did not have any mental illnesses.16 In the case of twins, the concordance
rates for schizophrenia are far greater among monozygotic twins (almost 50%) 17
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compared to fraternal twins who only share approximately 50% of the same genes.18, 19
Gene association investigations have identified several risk genes including dysbindin,
neuregulin, and Disrupted in schizophrenia 1 (DISC1), each influencing the N-Methyl Daspartic Acid (NMDA) receptor that contributes significantly to the pathophysiological
network of schizophrenia by causing neurotransmitter and synaptic anomalies.20-23
Genetic studies also have provided significant evidence showing dysregulation of certain
genes that control the metabolism of D-serine, an important modulator of NMDA
receptor (NMDAR).24 While genetic studies do not provide a clear description of specific
abnormalities underlying schizophrenia, there does seem to be a heritable genetic
component to schizophrenia.14

1.1.2 Neural models of schizophrenia:
Numerous models of schizophrenia have been developed to rationalize its onset
mechanism and the resulting brain abnormalities.25-31 Separate bodies of evidence have
been mounted in support of specific neurotransmitter abnormalities contributing to the
manifestation of symptoms. The earliest model recognized as the dopamine (DA)
hypothesis proposed that certain dopaminergic pathways are overactive. It was postulated
that the dysfunction in dopamine action on the ventral striatum region of the brain
surrounding the nucleus accumbens is likely a common feature of all patients with
schizophrenia.25 It had been postulated that over-activity of DA neurons situated in the
mesolimbic pathway, extending from the ventral tegmental area to limbic regions, may
have mediated positive symptoms.32 This hypothesis was initially suggested based on
findings showing that dopamine-blocking agents that generated symptoms similar to
those of acute paranoid and positive syndromes in schizophrenia.23 Unfortunately, this
model does not fully explain all symptoms, especially negative and cognitive
symptoms.26 Over the years, it was postulated that a dopamine neural pathway known as
the mesocortical pathway, which also originates from the midbrain’s ventral tegmental
area and projects to the limbic cortex, may have played a role in mediating some
cognitive deficits, mainly the negative symptoms of schizophrenia.25 Several
investigations also solidified the hypothesis that the hypoactive condition of the DA
neurons in the mesocortical region may be responsible for the negative symptoms.23, 27, 32
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Subsequently, a theory called the glutamatergic deficiency model of schizophrenia was
proposed that explains the appearance of negative symptoms disturbances of
glutamatergic neurotransmission upstream from the dopaminergic pathway.28 This model
was proposed a few decades ago after phencyclidine (PCP) was found to act on a specific
binding site on the NMDAR resulting in channel blockade and inhibiting receptormediated glutamate neurotransmission.34 In humans, it was discovered that PCP is
capable of inducing all of the symptoms of schizophrenia in healthy subjects, including
not only the positive ones but the prominent negative symptoms and cognitive deficits.34,
35

The previous literature indicates the abnormalities of glutamatergic neurotransmission

that play a vital role in the pathophysiology of schizophrenia and may account for its
manifestations.36
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Figure 1-1. The limbic basal ganglia thalamocortical circuits. ACC, anterior
cingulated cortex; CB, cerebellum; HIP, hippocampus; NA, nucleus accumbens;
PFC, prefrontal cortex; TH, thalamus; VT, ventral tegmentum.
Figure 1-1 illustrates the limbic basal ganglia thalamocortical circuits as two parallel
pathways that act contrastingly on the basal output nuclei. It has been suggested that
positive, negative, and cognitive deficits in schizophrenia may be associated with
dysfunction of the limbic basal ganglia-thalamocortical circuitry.31, 37 This pathway is
comprised of glutamatergic projections originating in cortical regions that transmit
excitatory inputs to the ventral tegmental area, which, in fact, exert an inhibitory output to
the thalamus.37, 38 Evidence indicates that an imbalance in the glutamatergic pathway, due
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to NMDA hypofunction that interacts with the cortex, limbic system and thalamus,
contributes to the development of schizophrenia.37 The hypo-functionality of the
NMDAR system is believed to prevent the activation of the cortical GABAergic
interneurons that, in turn, causes the disinhibition of the glutamatergic inputs in the
pyramidal neurons.37, 39 The glutamate model of schizophrenia postulates that a disruption
of the NMDAR function underlies the induction of the prominent symptoms of
schizophrenia, especially the negative and cognitive symptoms. Numerous studies have
also revealed possible glutamate-dopamine interactions by altering the activation state of
the NMDARs, suggesting the modulation of dopamine release by glutamatergic
neurotransmission.37, 41-45
Several lines of evidence support that the hypofunction of the NMDAR is due to its
dysregulation rather than a reduction in its numbers. Both clinical trials and pre-clinical
investigations indicate that the administration of the agonists of the glycine modulatory
site (GMS), that modulates the NMDAR, could restore the NMDAR function.46 The
activation of the NMDAR relies on the simultaneous binding of glutamate and an agonist
D-serine (or glycine). The enhancement of binding to the GMS is more effective than
attempts to increase glutamate binding. GMS binding increases NMDAR function
effectively, and does not induce neurotoxicity.47Among all GMS ligands, D-serine is
known to be the primary co-agonist for synaptic NMDAR.48-55 Thus, it has been proposed
to test the validity of D-serine supplementation as a therapeutic agent targeting the GMS
in order to augment the NMDAR function.56, 57 Some suggest this approach could be a
crucial advance for the treatment of the most prominent symptoms of schizophrenia not
well controlled by current DA-based medication, i.e. the negative and cognitive
symptoms.29

1.1.3 D-Serine as adjuvant to antipsychotic Treatment:
Since it has been postulated that the dysfunction of glutamate neurotransmission mediated
by the NMDAR is implicated in the pathophysiology of schizophrenia, the complete and
partial agonists of this receptor have been examined in a series of studies as possible
modulators of glutamate neurotransmission. Modulation of the NMDAR activity can be
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augmented by facilitating glutamatergic signaling via the use of compounds such as
NMDA co-agonists (i.e. D-serine, glycine) and glycine transport (Gly-T) inhibitors.58
Some promising reports have demonstrated the efficacy of high doses (approximately 60
g/day) of glycine, a direct co-agonist of NMDAR in alleviating the negative and cognitive
symptoms of schizophrenia.59-62 Despite confirmation of the efficacy of glycine provided
by two meta-analyses,63, 64 more investigation should be performed using larger samples
to confirm the effectiveness of oral glycine administration in facilitating NMDAR
neurotransmission. It has also been noted that the administration of high concentrations of
glycine may cause extensive excitotoxicity 64 and hyperexcitability.83 In contrast, other
NMDAR agonists, including D-serine and D-alanine, did not produce any neurotoxicity;
previous studies revealed that this condition is a selective effect of glycine.82, 83 Gly-T
inhibitors may also be used to enhance the glycine synaptic levels by preventing its
reuptake without producing any adverse effects.65 In preclinical studies Gly-T inhibitors
have proven to enhance NMDAR function in schizophrenia, 67-78 though the number of
studies performed on humans is limited and poorly investigated.66,67,79-81
D-serine enables the activation of the receptor, producing full agonism and induces
maximum activation of the NMDAR glycine site, and thus the antagonistic effect
produced by other partial agonists is avoided.84, 85 Not only does D-serine have a higher
affinity for the GMS, it also crosses the blood brain barrier more readily compared to
glyicne 29 and L-serine; 86 it is enriched within the corticolimbic areas 87 and its regional
distribution and age related changes correlate well with the NMDARs.88, 89 Therefore, Dserine is an attractive candidate as an adjuvant to current antipsychotic treatment. A
number of clinical trials have examined the co-administration of D-serine along with
standard antipsychotic medications in schizophrenia. Unfortunately, some clinical trials
have found confounding results in terms of the efficacy of D-serine and glycine
administrations to relieve the prominent symptoms, mainly due to their ineffective oral
bioavailability.47 The confounding results in studies that included the use of D-serine may
also be due to variations in pharmacokinetic profiles 90 and the doses of D-serine being
used. A clinical trial investigated the addition of D-serine to treatment of patients with
chronic schizophrenia resulting in the significant improvement of positive, negative and
cognitive symptoms 91 and another following trial demonstrated a significant reduction in
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all of the symptoms in risperidone or olanzapine-treated schizophrenia patients after the
administration of D-serine.92 Although, a decline in symptoms was observed in previous
studies, two clinical trials were performed with a larger sample of acutely ill population,
93

and chronic patients 94 and the results indicated no significant improvements. A double-

blind investigation of D-serine at high doses (approximately 60mg/kg and 120mg/kg)
verified a significant improvement in neuropsychological scores and the symptoms, 97 in
spite of the concerns raised about its safety issues. More clinical trials are warranted to
examine the optimum clinical dose of D-serine that provides a safe and effective
therapeutic benefit.92, 95, 96 Clinical studies have examined the effects of D-serine addition
and its dose-dependency in plasma levels, nonetheless; ideal doses of D-serine need to be
determined.35, 97 There is currently no method to determine oral dosage of D-serine for a
given individual because the amount crossing the blood brain barrier will vary
significantly between patients.
Clozapine was revealed to have a greater impact for improving positive and negative
symptoms in comparison to other conventional medications.98 Unfortunately, it has not
been applied as the first-line of treatment due to its serious side effects.99A few studies
have indicated that the effectiveness of clozapine in treatment of primary negative
symptoms is inadequate.100 Nevertheless, clozapine is currently part of the standard of
care for patients that do not respond to first-line antipsychotic medication. Previous
reports have demonstrated the efficacy of the co-administration of D-serine, glycine, and
D-cycloserine, a partial agonist, in conjunction to non-clozapine conventional
neuroleptics for improving negative deficits in patients with schizophrenia.5, 91, 97, 101-105
The co-administration of D-cycloserine which caused deterioration of positive and
negative symptoms, 106-110 glycine, 111 and D-serine did not have any potentiated effect nor
did it worsen the symptoms 85 when administered with clozapine. The combination of
non-clozapine antipsychotic drugs along with effective adjuvants aimed at glutamate
modulation through the GMS may provide potential therapeutic effects for patients with
schizophrenia.
A recent meta-analysis has revealed the inefficacy of certain glutamate positive
modulators on cognitive functions in patients with schizophrenia.103 This systematic
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review mostly highlights studies that target and enhance glutamatergic neurotransmission.
These reports indicate the ineffectiveness of the use of compounds that mainly act on the
AMPA receptors or positively modulate the NMDARs and some few reports
investigating the action of amino acids (i.e. D-serine, D-cycloserine and glycine) on the
glycine site of the NMDAR. On the contrary, other studies have proven the beneficial
effects of NMDA-enhancing agents via the glycine site.57 The doses of D-serine and
glycine that were administered in these studies were not monitored properly and not
adjusted for body weight (an important factor when considering the administration of
glycine).43 Clinical trials often include a wide range of participants who may have several
types of responses to the treatment. Because schizophrenia is such a heterogenous
disease, it is important to properly stratify patients for fear of obtaining inconclusive
results due to inclusion of subgroups with confounding responses to the treatment. There
has not been very good means or methods by which to stratify participants in clinical
trials so far. Therefore, this review may indicate the poor efficacy of agents that act on the
glutamate receptors directly but lacks conclusive information on the inefficacy of
compounds that modulate the NMDAR at the GMS in improving cognition function in
patients with schizophrenia.103

1.1.4 Evidence of abnormal levels of D-serine in schizophrenia:
A few other post-mortem studies were conducted in order to assess abnormalities in
metabolites for those diagnosed with schizophrenia. Significant irregularities of brain
gross anatomy and histology have been identified in specific post-mortem brain structures
of adults with schizophrenia compared to controls. A reduction of glycine was observed
in the plasma of medication-native patients 112 and a lower glycine values was
proportional to the severity of the negative deficits.112-114 Considerable reductions of Dserine levels were observed in the cerebral spinal fluid (CSF) content of medication-naive
subjects with schizophrenia, 115, 116 in the serum of patients, 117-119 and in the putamen of
untreated patients.120 Conversely, some post-mortem investigations have reported that the
levels of total serine (D and L-serine) and glycine showed a higher level of these amino
acids in the medial temporal lobe areas of schizophrenics when compared to controls.146
No changes were observed in the amount of free D-serine in the prefrontal and parietal
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cortices in patients with schizophrenia, suggesting regional dysfunction in serine
hydroxymethyltransferase (SHMT), an enzyme that cleaves serine to glycine.121,144-147
Significant correlations were found between the levels of Km SHMT and these amino
acids in temporal but not in the frontal lobes in schizophrenic patients.145 It has been
suggested that the exposure to neuroleptics could induce the abnormal SHMT activity in
the temporal lobes.145 Other reports indicated a relatively low concentration of D-serine in
the cerebellum and spinal cord, which was similar to examinations of rodents 121 and the
decreased serum levels of D-serine/total serine ratio in these patients,148 corroborating the
NMDA hypo-function hypothesis of schizophrenia. These studies supported the
assumption that the distribution of D-serine and NMDA receptors are correlated in the
human central nervous system (CNS), as suggested in the rodent study.121,144 In vitro
studies have indicated that the reduction of D-serine impairs the NMDAR activity 122-127
and, contrastingly, the enhancement of its levels increased the NMDAR activities 128-130
and improved symptoms in patients.131 Post mortem studies have also revealed
abnormalities in the expression of D-serine regulatory enzymes.96 Consequently, D-serine
and its modulatory enzymes may monitor NMDAR functioning, and any irregularities in
this pathway may induce NMDAR dysfunction. These studies indicate the importance of
quantifying the amino acids and neurotransmitters that interact with the NMDA glycine
receptors, and also of developing a refined technique that can monitor the changes in
these metabolites because they underlie the pathophysiology of schizophrenia.

1.1.5 Previous 1H-MRS studies of serine and glycine:
Proton Magnetic Resonance Spectroscopy (1H-MRS) studies assess and quantify several
metabolites and neurotransmitters present in the human brain.132 A method for assessing
changes in in vivo serine and glycine, could be critical to demonstrating abnormalities of
endogenous levels in schizophrenia or to the validation of the brain dose achieved in a
study using serine/glycine as an adjuvant to standard treatment. Thus far, no 1H-MRS
studies have examined the endogenous levels of serine in the psychiatric population.
Conventional 1H-MRS cannot detect serine due to its relatively low levels in the human
brain, a complex spectral signature, and interference from the neighbouring
metabolites.133-135 Previous reports have employed advanced 1H-MRS techniques,
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conducted at higher field strengths of 4.0 Tesla (T) 134 and 7.0 T 135, respectively, to
measure in vivo endogenous serine concentrations in healthy subjects. Until now, no prior
investigations have attempted to measure human brain serine on the more widely
available, clinical field strength, 3.0 Tesla scanners. There has been no 1H-MRS
schizophrenia study conducted for detecting serine non-invasively. However, the
advanced methods mentioned above hold the promise to be applicable to the study of
schizophrenia, especially if the technique can be implemented on a 3.0 Tesla scanner.
Since both D-Serine and glycine can bind to the NMDA GMS, it may be relevant to the
glutamatergic models of schizophrenia to study glycine in addition to serine.136, 137
Detection of glycine has also been challenging using conventional 1H-MRS methods at
short echo times due to its low concentration and MRS signature overlap with signals
from macromolecules and myo-inositol.138, 139 Most studies have focused on investigating
the glycine levels in cancerous regions 140-142 since it has been detected as a biomarker in
brain tumors.139 One study has been able to test changes in levels of glycine after its highdose administration as adjunctive therapy in healthy men using 1H-MRS.143
Until now, conventional 1H-MRS techniques have been unable to reliably measure
important neurochemicals such as serine and glycine due to their low concentrations and
low sensitivity due to spectral overlaps with the signal of other metabolites. Thus, it is
crucial to develop advanced 1H-MRS methods capable of detecting these metabolites to
enable their application in studies of schizophrenia and its treatment. Chapter 2 will
present our implementation of such a technique.

1.1.6 The thesis outline:
This chapter covered background information, a brief history and description of the
mental disorder schizophrenia, toward which the work of this thesis is aimed. This
chapter also presents a literature review concentrating mainly on investigating the
efficacy of the co-administration D-serine along with standard treatments of
schizophrenia.
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Chapter 2 is a general introduction to the fundamental principles of proton magnetic
resonance spectroscopy and its application in in vivo. It is meant to expand on the
theoretical foundation necessary to understand the material presented in Chapter 3 that
would not typically be included in a peer-reviewed article format due to space limitations
and less didactic nature.
Chapter 3 describes a report on test-retest reliability protocol performed on phantoms to
demonstrate the within and between session variability of the data obtained with the
implemented novel DANTE-PRESS 1H-MRS sequence. The in vitro results were used to
estimate serine concentration measurement precision and accuracy. This report also
demonstrates an in vivo proof of concept data, which was acquired in a group of four
healthy participants.
Chapter 4 presents a general concluding statement on the material described in Chapter 3
and it discusses the limitations of the presented study. This chapter also provides
suggestions in managing the limitations of this study in future studies using the technique
and possible future applications to measurements of other metabolites.
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Chapter 2

2

Introduction:

The discovery made by Stern and his collaborators in 1933 on the magnetic moment of
protons inspired Rabi to develop a technique which more precisely detected the
magnitude of the moment.1, 2, 3 In September 1937, Dr. Gorter engaged in simulating
experiments that determined the nuclear moments from the changes made in the
temperature of solids while located in a constant magnetic field.4 Later, a molecular beam
apparatus was created by Rabi and his team, which was capable of investigating the
magnetic resonance properties of individual elements, including Hydrogen, 2 Lithium, 4
and Deuterium.5, 6 It was not until 1946 that Purcell 7 and Bloch 8 independently
demonstrated the nuclear magnetic resonance (NMR) properties in solids and liquids. In
1952, both scientists were awarded the Nobel Prize in Physics for their discovery of
NMR.
The following paragraphs will describe the fundamental principles of nuclear magnetic
resonance (NMR) physics and proton magnetic resonance spectroscopy concepts that are
related to the work presented in this thesis.8–68

2.1

Principles of magnetic resonance imaging and spectroscopy:

The three main types of magnetic fields used in MRI, i.e, the external main magnetic field
(B0), the radiofrequency (RF) field (B1) that excites the spin, and linear gradient (G) fields
that provide localization, influence the energy state of a nucleus with a nuclear magnetic
moment μ. In the presence of an external magnetic field (B0), these vectors tend to align.
The applied force on the magnetic moment due to B0 induces the magnetic moment to
precess at a fixed angle. The relationship between the precession frequency that the
nuclear spins exhibit and the magnetic field strength was defined first by Sir Joseph
Larmor. It is proportional to the magnetic field strength and is given by the following
equation 0 = B0. The symbol/variable  stands for the gyromagnetic ratio, which is a
property of each type of nucleus. A hydrogen proton possesses a  value of 267.52 * 106
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rad/(s*T), therefore for a 3.0 Tesla (T) field the resonance frequency equals
approximately 128 MHz, which is in the FM radiofrequency (RF) range.
Several nuclei (1H, 13C, 19F, 23Na, 31P) are known to possess a spin angular moment but
among all, hydrogen (with an angular momentum of spin of ½) is the most used atom in
the MRI practice since it is the most abundant molecule in the human body. When 1H
nuclei experience an external magnetic field, a slightly greater number of protons will be
in the lower energy state (longitudinal magnetization parallel to the main magnetic field)
when compared to the higher energy state (anti-parallel to the main magnetic field). The
parallel state possesses a lower energy and this condition causes an energy difference
between the two states which corresponds to the energy of a photon at the Larmor
frequency. The vector sum of all magnetic moments within a small region of space
containing spins precessing at the same frequency (a.k.a isochromat) is denoted as net
magnetization (M0), as illustrated in Figure 2-1. The net magnetization acts as a vector
with three components with respect to B0, each evolving as a function of time, known as
longitudinal Mz(t), and transverse planes My(t) and Mx(t).
As illustrated in the following figure, a net magnetization M0 is produced along the
parallel state aligned with B0.
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Figure 2-1. This figure represents the relative population size of the two possible
energy states (Eigen states). This does not represent the state of individual spins, but
any single spin is in a superposition of the two Eigen states. This illustration is
adapted from Figure 1-6 in [66].

A condition known as the equilibrium state of magnetization is induced when the net
magnetization vector is aligned with the static main field B0, where the M0 will form
along the z-direction. In order to generate an MR signal, a non-equilibrium state must be
achieved by applying a rotating RF magnetic field (B1), oscillating at the Larmor
frequency in the x-y (transverse) plane. The presence of a rotating RF magnetic field, B1,
will result in the rotation of the M0 towards the x-y plane, and will tip it away from its
initial direction (z-axis), perpendicular to the direction of the B0. The tip angle of the RF
pulse applied is dependent on the strength of the RF magnetic field and the duration of the
pulse. To achieve maximum signal, a 90° (excitation) pulse must be applied in order to
tilt the M0 completely onto the transverse plane. A 180° flip angle (a refocusing pulse)
can be obtained by doubling either the duration or a voltage of an RF pulse (hard pulses).
The research presented in this thesis applies a type of spin echo sequence that will be
discussed and it consists of an excitation pulse followed by three 180° refocusing pulses,
one of which is a frequency-selective RF pulse.
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Once the excitation RF pulse is terminated, the net magnetization will continue to precess
about the z-direction at the Larmor frequency and the spinning nuclei will return to the
equilibrium distribution. The process by which the excited protons return to their original
equilibrium orientation is known as relaxation. There are two NMR relaxation states
referred to as T1 and T2 relaxation time constants; the terms characterize the recovery of
Mz, longitudinal or ‘spin-lattice’ relaxation, and the decay of the Mx and My components,
transverse or ‘spin-spin’ relaxation, respectively. The process of T1 relaxation time
describes an exponential regrowth of longitudinal magnetization, and is the period
required for the z component of M to restore 63%, [1-(1/e)], of its initial value. At
thermal equilibrium, the phase between the nuclei is incoherent. A collection of spins that
are “alike”, meaning they possess the same chemical environment and experience a
similar applied magnetic field, are referred to as isochromats. Following an excitation
pulse, the spins are tipped onto the transverse plane due to the presence of the B1 field,
and the phase coherence between isochromats is attained. The spin-spin relaxation time
(T2) characterizes the decay of transverse magnetization, and it is caused by random
fluctuations of the local field produced from the movement between nearby protons that
cause a loss of phase coherence (even within isochromats). Due to static field
inhomogeneities (field that varies between isochromats), the transverse magnetization
decays more rapidly and accelerates the dephasing of the spins. This observed decay rate
of the signal is said to have a characteristic time constant denoted as T2*.9 Finally, after an
excitation pulse is applied, an MR signal is characterized by a Free Induction Decay
(FID), which is generated as the net transverse magnetization gradually decreases
exponentially in time as the spins lose their phase coherence (FID signal is the sum of
signal from a large number of isochromats located within the voxel). A receive coil (for
example, a head coil) is capable of detecting the voltage varying at the resonant frequency
(0) which is induced in the coil by the precession of M0.
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2.2

Signal localization:

A pulse sequence consists of the collection of radiofrequency (RF) pulses and gradient
pulses with specific durations and timings, capable of generating MR images or spectra.
The magnetic field gradients in MR allow for the production of a localized signal which
is achieved by applying gradient pulses (known as slice select gradient, abbreviated as Gs
or Gss) that results in a linear variation of resonance frequencies along any of the three
orthogonal planes (the x, y or z axes), and an RF pulse tuned to the Larmor frequency
simultaneously. The thickness of the excited slice is determined by the strength of the
gradient pulse and the RF pulse’s bandwidth. Note that the waveform of an RF pulse (i.e.
its time-dependent amplitude modulation) greatly affects the excitation profile of the
magnetization. The goal is to only have the signal that is appropriately refocused at the
intersection of all three excited planes to generate a signal (the region of interest). This
process allows for a selective excitation of a volume at the intersection of the three slabs
and generates a voxel with a specific position, size and shape. The simultaneous
execution of the 90° RF pulse (the first RF pulse) along with its magnetic field gradient
(i.e. along the x-axis) generates a FID which selectively selects spins from a slice. The
first spin echo produced by the simultaneous execution of magnetic field gradient
perpendicular to the previous gradient (i.e. along the y-axis) and the first slice-selective
refocusing pulse (180° RF pulse) contains signal from a bar at the intersection of the two
orthogonal slices. The second spin echo is achieved by the simultaneous application of a
magnetic field gradient along the last remaining orthogonal axis (i.e. along z-axis) and the
second slice-selective 180° RF pulse and will produce signal only from the intersection of
the three orthogonal slices, as illustrated in Figure 2-2. Pairs of gradient crushers
adjoining the two refocusing 180° RF pulses ensure the selection of the preferred signal
and the elimination and the dephasing of any unwanted coherences (echo responses)
generated from the outside of the voxel (which may cause artifacts) or from spins having
received the wrong flip angle (i.e. at the edge of RF pulse passbands). For more
information on the optimization of the gradient crushers for the proper dephasing of the
unwanted coherences performed for this study visit Appendix C.
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Figure 2-2. A three-dimensional single voxel localization process. The intersection of
the three planes selected by the three RF pulses executed simultaneously with their
respective slice-selective gradients results in the production of MR signal only from
the desired VOI. Signal outside of the VOI is dephased (via the gradient crushing).
This image was adapted from Figure 1.8 in [67].

2.3

Chemical shift:

Due to the applied external magnetic field, an induced magnetic field (a secondary
magnetic field) is generated by the circulation of electrons surrounding a nucleus. The
electrons carry a small charge and therefore exert a smaller effect on the nucleus
compared to the external field, sufficient to produce a unique molecular spectrum that
distinguishes them. Depending on the extent of nuclei shielding by the surrounding
electron cloud, the absorption position shifts either to the right (up field) or to the left
(down field) of the NMR spectrum. This phenomenon is known as chemical shift.
Chemical shift is expressed as the following 16:
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ω = γB0 (1 - σ)

Overall, ω is the local precessional frequency of the resonance that corresponds to a
certain molecular compound and σ stands for the electronic shielding constant that is
dependent on the chemical environment. As the formula states, the displacement of the
resonance frequency is proportional to the main magnetic field B0. The change in the
strength of the external magnetic field is linearly proportional to the change in the
magnitude of a chemical shift represented in Hertz. Therefore, the magnitude of the
chemical shift for a given compound is commonly characterized in parts per million
(ppm), and is independent of the strength of the external magnetic field. The value for
chemical shift is determined by the differences between the absorption peak of a
resonance frequency of a particular proton and the absorption peak of a reference proton.
In this thesis, for measurements of the naturally occurring metabolite, serine, located at
3.83 ppm, the reference is chosen to be N-Acetylaspartic Acid (NAA), situated at 2.01
ppm. Serine resonates to the left of NAA since its nuclei are less shielded and resonate at
a higher frequency. Overall, the magnitude of the chemical shift is dependent on the type
of the nucleus and the varying electronic environment of the proton.

2.4

J-coupling and spin systems:

Not all protons have the same resonance frequencies according to their chemical
environments and locations. Nuclei subjected to a similar chemical shift or chemical
environments are known to be equivalent, while those experiencing different chemical
environments are non-equivalent. A J-coupling or spin-spin coupling effect can be
observed on the NMR spectrum, when non-equivalent nuclei exert an influence over the
effective magnetic field of the adjacent nuclei. The number of peaks represents the
number of protons present in a molecule or a compound. In most cases, the NMR
spectrum displays a combination of multiple peaks rather than a single peak that has
arisen from a solitary proton. Thus, the signal will be split into two or more separate
peaks (doublets, triplets, multiplets etc) and the overall area under all these peaks will be
the same as the total area under the corresponding singlet peak that would arise in the
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absence of the J-coupling effect. The J-coupling constant represents the fixed frequency
difference between the centres of the multiplet peaks and, unlike the chemical shift; its
value is presented in Hertz. The two factors of J-coupling constant and the chemical shift
value aid in describing the spectral signature of each compound in the sample.
This thesis mainly focuses on measuring serine, with a molecular formula of C3H7NO3, a
strongly coupled metabolite composed of a three spin system known as ABX.54

Figure 2-3. The chemical structure formula of serine is presented. This figure was
adapted from [68] and was further modified to number the carbon atoms.

The splitting of A resonance occurs in the presence of the two different spins. This spin
system is generated by the presence of the 2CH and 3CH2 groups that form doublet-ofdoublets and have closely located resonances of 3.83, 3.94 and 3.98 ppm, respectively.17
This causes the resonances of serine to overlap, thereby making their identification and
quantification difficult. Improved detection of serine with a complex spin system can be
achieved through the use of a modified proton magnetic resonance spectroscopy (1H-
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MRS) technique, which will be described in more detail in Chapter 2. This method allows
the selective excitation of the resonance of serine at 3.83 ppm (the X pattern) as indicated
by the arrow in the figure below. This X spin resonance of serine has the least signal
contamination from the neighbouring metabolites, including a large singlet methylene
resonance of creatine located at 3.92 ppm, 55 thus making the detection of this spin pattern
more ideal when compared to the other two resonances.

Figure 2-4. Resonances of serine and neighboring metabolites are
illustrated above. The ABX pattern is recognized based on its AB and X
multiplets. The AB portion consists of an unsymmetrical 8 line pattern,
and the X part includes a symmetrical 4 line pattern as shown above. As
shown, the X pattern has the least interference from neighboring
metabolites (A simulated FID 1Hz LWs).
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2.5

Proton magnetic resonance spectroscopy:

Nuclear Magnetic Resonance (NMR) Spectroscopy is a powerful MR-based modality that
allows the characterization and determination of the molecular structure of certain
metabolites and the examination of biochemical concentrations in vivo. The term
“nuclear” may lead to misinterpreting its association with nuclear medicine and radiation,
thus in vivo NMR is otherwise identified as Magnetic Spectroscopy Resonance (MRS).
MRS is a valuable modality that can be applied to investigate metabolic changes in
neuropsychiatric disorders and to follow the effect of treatment due to its non-invasive
and repeatable nature. The investigation of neurochemicals using proton MRS could
provide valuable insight into the possible mechanisms underlying neurotransmitter
receptor function. Proton MRS allows the measurement of molecules with relatively low
concentration levels (0.5-1.0 mM), but this typically requires the use of non-standard
MRS pulse sequences. This thesis will focus on the use of an advanced single voxel
spectroscopy (SVS) technique known as Delays for Alternating with Nutation for
Tailored Excitation (DANTE)-PRESS 55 that uses very narrow-band RF pulses to
selectively refocus the signal from metabolites of interest, thereby simplifying the
resulting spectrum. This metabolite-selective DANTE-PRESS technique is of particular
interest in the detection of metabolites with strongly J-coupled spin systems.

2.6

DANTE-PRESS sequence:

One of the most commonly used pulse sequences in acquiring in vivo single-voxel proton
(MRS) data is known as point-resolved spectroscopy (PRESS).23 Generally a PRESS
sequence consists of three broadband radiofrequency pulses (typically a 90° excitation
pulse followed by two refocusing 180° RF pulses) that are applied in the presence of
gradients along one of three orthogonal axes in order to select a specific threedimensional volume known as a voxel. A conventional symmetrical PRESS sequence
creates a double spin echo that is generated at a time TE/4 after the second 180°
refocusing pulse, where TE is the echo time of the sequence. The gradient crusher pairs
placed on each side of the two refocusing pulses ensures the dephasing of signal
generated outside of the voxel of interest (VOI).
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In this thesis, the presented work has been obtained by using a customized, metaboliteselective 1H-MRS sequence, DANTE-PRESS (D-PRESS), 55 which required the
implementation of a frequency-selective, Gaussian modulated, single-DANTE pulse into
a symmetrical PRESS sequence placed at the midpoint between the two 180° refocusing
pulses (Figure 2-5).
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Figure 2-5. Pulse sequence timing diagram for the 1H MRS acquisition
protocol (DANTE-PRESS) employed in the experiments reported in this
thesis. This schematic diagram shows the timing and the order of the RF
pulses and the gradients pulses. The bracket shows the DANTE module
(the DANTE RF pulse and its crusher pairs) added to a standard
symmetric PRESS sequence.
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The single-DANTE RF Pulse excites a repeating pattern of narrow passbands that can be
centered on the 3.83 ppm resonance of serine and a reference metabolite, NAA, by
producing a frequency-domain inversion profile with Gaussian passbands (Full width at
half maximum, FWHM = 15 Hz) repeating every ~ 223 Hz. The frequency domain period
(FDP) is an important parameter that represents the distance (frequency difference) in
between two successive passbands of the DANTE pulse in the frequency domain.
Depending on the FWHM (a parameter that describes the width of an RF pulse) value of
the DANTE RF pulse inputted by the user, the pulse sequence dynamically generates a
DANTE pulse with the requested characteristics. Figure 2-6 illustrates the DANTE RF
pulse generated by the pulse sequence when the bandwidths requested by the user were
15 Hz and 100 Hz, respectively.

Figure 2-6. A frequency selective single-DANTE pulse, generated with
bandwidth values of 15 Hz (on the left; duration of 118.54 ms, with FDP value of
223 Hz) and 100 Hz (on the right; duration of 18.35 ms, with FDP value of 223
Hz), respectively. These simulations were generated in the IDEA pulse
programming environment via POET, an offline user interface mimicking the
user interface of the MRI scanner (IDEA, Version VB20PSP4, Siemens,
Erlangen, Germany).
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A bandwidth of 15 Hz ≅ 0.11 ppm is sufficient to produce a frequency range needed to
excite the X pattern and isolate the resonance of serine at 3.83 ppm at a 3.0 T scanner.
This frequency-selective RF pulse enables the selection of serine resonances and
elimination of interfering resonances from other metabolites. The signal of unwanted
metabolites is destroyed completely due to the optimized crusher gradient pairs placed
directly around the DANTE RF pulse along each axis, as demonstrated in figure 2-7.
Signals are only produced by the spins that were affected by all four RF pulses of the
DANTE-PRESS sequence. Resonances outside the passband of the pulse are eliminated
by strong gradient crushing as shown in the image below (Figure 2-7). More details on
the DANTE-PRESS sequence are presented in the next chapter.

Figure 2-7. Top spectrum displays a conventional MRS in vivo data
acquired with a symmetrical PRESS sequence (TE=286ms). Bottom
spectrum displays in vivo data obtained with the serine metabolite-selective
protocol (DANTE-PRESS, TE= 286 ms, FDP = 2000 Hz, which only
refocuses the serine resonances at 3.83ppm. A slight creatine contamination
can be observed).

2.7

Water suppression:

In order to reliably detect metabolites signals of interest within a selected volume of
tissue, the water peak must be suppressed. The human brain contains approximately
50,000 mmol/L of water, which is approximately four orders of magnitude larger
compared to the concentration of metabolites (approximately 1-10 mmol/L).23 It is crucial
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to saturate the water peak originating at approximately 4.7 ppm to avoid baseline
distortions that may affect metabolites with resonances near that range, specifically serine
(range of 3.93 ppm to 3.83 ppm).17 Prior to the measurement of metabolites of interest
and the start of the single-voxel localization sequence, a chemical shift selective (CHESS)
28

technique is implemented that usually involves a series of three Gaussian shaped

narrow-band, frequency-selective RF pulses, centered at the resonance of water. Each of
these RF pulses is followed by a spoiler gradient, which ensures the complete dephasing
of the selected water signal. These pulses have long durations, which affect signals within
a narrow range of frequencies (i.e. 20 to 60 Hz) and avoid the disruption of the spins of
the other metabolites. To achieve optimal water saturation, the flip angle values of the
CHESS pulses must be optimized after the manual shimming of B0 is performed. This
task ensures best water suppression by iteratively minimizing its residuals via fine
adjustment of the RF power of these pulses. Despite careful adjustments, the water peak
is usually not eliminated completely. The remaining residuals can be removed during
post-processing by using a water subtraction technique such as the Hankel-Lanczos
Singular Value Decomposition (HSLVD, using JMRUI software) 35 prior to quantifying
metabolites. A common problem associated with 1H-MR Spectroscopy, aside from water
contamination, is the presence of broad macromolecule peaks, which are abundant near
the resonances of serine.52, 53 On a positive note, this thesis focuses on the use of a long
echo time that eliminates the interference from the macromolecular signals.

2.8

MRS quantification methods, line shape corrections:

Magnetic field perturbations, eddy currents, arise from switching field gradients.38
Spectral artifacts are generated under the influence of eddy currents and B0
inhomogenities resulting in distortions of the lineshape of each peak of the spectrum. A
post-processing approach, Quality Eddy Current Correction (QUECC) 39, 44, is applied to
correct the lineshape distortions caused by the effect of eddy currents and B0
inhomogeneities in preparation for spectral fitting assuming specific lineshapes. The
QUECC technique is a combination of two other methods, QUALITY 36, 44 and ECC.38
This lineshape correction process is achieved by using a reference peak with a
representative lineshape, usually the water peak from a water-unsuppressed acquisition
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obtained with the same gradient arrangements. This reference is used to correct for the
time-dependent phase and/or the amplitude of the complex signal obtained from the
original data. This procedure allows for the restoration of Lorentzian lineshapes that in
turn enables the data to be fitted more effectively using spectral models with known
lineshapes and better minimize the differences between raw data and the spectral model,
known as residuals. The intensity of the water peak is larger than the metabolite of
interest and any minimal errors in estimation of fitting the water signal will cause
significant error in metabolite concentrations. Thus, it is important to note that both the
water reference and the data must be lineshape-corrected.

2.9

Spectral fitting:

After the performance of the lineshape correction and the complete removal of the water
peak, the data is ready to be quantified. Each metabolite produces a unique spectral
signature and some metabolite signatures can and will overlap in an in vivo spectrum. The
area under each metabolite signature (sum of its peaks time domain amplitudes) is
proportional to the concentration of that particular metabolite. In order to isolate the
contribution of the signal of interest among contaminating signals and to quantify a given
metabolite’s concentration level, it is crucial to develop a priori knowledge 42-44 of the
metabolite signatures which are specific to the selected pulse sequence and selected
timing parameters (i.e. TE). There are two general approaches for generating prior
knowledge: scan of metabolite solutions or simulations (density matrix or product
operator formalism). 27, 31, 42-44, 57-65
In this thesis, we chose to acquire prior knowledge from metabolite solutions. Aqueous
phantoms (pH 7.31, similar to in vivo) were prepared with metabolites of interest and a
reference that have equal concentration levels to the ones expected in the human brain.17
A prior knowledge template for the metabolites was derived from in vitro experiments,
obtained from the prepared brain-mimicking phantoms. The in vivo template included the
modelling of five metabolites (serine, creatine, glutamate, glutamine and NAcetylaspartic Acid) obtained from in vitro experiments. These five metabolites were
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selected because they have resonances near the 3.83 ppm serine resonance used in serineselective acquisitions.

2.10 The fitting procedure:
A locally-developed spectral fitting software (iterative fitting algorithm) called Fitman
(Fitman Spectral Analysis Suite) 42 was used to determine the amplitude of metabolite
peaks (area under metabolite signature) in preparation for quantification of the metabolite
concentrations. This fitting procedure uses a template created from manual modeling of
the resonance pattern of each individual metabolite and incorporating them into a single
model (constrained sum of individual metabolite models). These individual metabolite
models included the information of all the metabolite peaks (amplitudes, line-widths,
chemical shifts, and phases). The spectra were fitted based on the information provided in
two separate files known as “.ges” that included the initial estimates of each peak
parameter and “.cst”, which contained a set of constraints of the minimization procedure.
This process uses a non-linear minimization of the residuals of a fit (i.e. the data
subtracted by the fit) and determines an estimate of all of the metabolites’
concentrations.42 The following figure illustrates the fitting components of each
metabolite, the residual fit, and the data of an in vivo spectrum.
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Figure 2-8. Representative in vivo spectrum obtained from the left
anterior cingulate of a healthy participant. Line (A) represents the
data in black and the fitting line in red, lines (B, C) represent the
fitting components of serine and creatine in orange and purple,
respectively, lines (D, E) illustrate the fitting components of
glutamate and glutamine in green and pink, respectively. Line (F)
represents the residuals of the fit in blue. (Line broadening factor
of 2 Hz was used for display only).

2.11 Quantification of metabolites:
Quantification of magnetic resonance signal amplitude can provide an estimation of a
metabolite’s concentration based on the metabolite areas determined by fitting of the
spectral model. In order to account for scan-to-scan variability in metabolite area
estimates, it is essential to obtain an internal concentration reference signal affected by
the same sources of variability. The unsuppressed water signal from a voxel is typically
used as a concentration reference, which can be seen as the denominator in the following
general quantification formula for metabolite concentration in mM:
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Equation (2-1)
Aside from the areas of metabolite(s) and water, as the formula states, the following
factors are taken into consideration: Mgain and Wgain which represent the receiver gain
for the metabolite and water spectra, respectively, ScaleM and ScaleW represent the
scaling factors of the raw data and the water data, respectively (occurs during conversion
of MRS data file from the manufacturer’s format to the fitman “.dat” format), the number
of protons of metabolite(s) and water indicated as protonsM and protonsW (i.e. 2 protons
per water molecule) and water_percent represents the water content within a voxel.

Equation (2-2)
In this thesis, we assumed that the voxel was entirely made up of grey matter (81% water
content) and therefore, only the fractional component of grey matter was taken into
account. The water_percent formula includes the density of water at 38 Celsius (the body
temperature (0.99299g/cm3)) and the molecular weight of water at body temperature
(18.0152g/mol) denoted as water_density and water_MW, respectively.
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2.12 Summary:
In conclusion, this thesis introduces the implementation of an advanced proton magnetic
resonance spectroscopy protocol, DANTE-PRESS, at 3.0 T that enables the detection of
metabolites with complex spectral signatures. This chapter has presented a general
description of this advanced MRS protocol. This technique is a novel approach that looks
promising for in vivo applications that will be described more specifically in the
following chapter. For more information see Appendices A, B and C.
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3

Reliability of in vitro measurements of endogenous levels of
serine using DANTE-PRESS 1H-MRS at 3.0 T.
3.1

Introduction

Over the last two decades, there has been a growing interest in investigating the in vivo
assessment of endogenous serine (Ser) levels in the frontal region of the human brain.
Researchers have explored its implications for understanding the pathophysiology of
neuropsychiatric disorders, especially schizophrenia.1-4 Ser is one of the naturally
occurring amino acids present in the human brain, regulating glutamate
neurotransmission at the glycine site of the N-methyl-D-aspartate (NMDA) receptor,
serving as an endogenous co-agonist.5-8 Increasing evidence for dysfunction within the
glutamatergic molecular cascade in schizophrenia implies a need for further investigation
of glutamate modulatory agents via the NMDAR glycine binding site.9 Several lines of
evidence suggest that abnormalities of the glutamate neurotransmission system in
schizophrenia are possibly caused by the alteration in Ser signaling, suggesting that the
administration of D-Ser may provide a new treatment strategy.10-11 It has been suggested
that some of the most debilitating features of this mental disorder, including the negative
(-) and cognitive (c) symptoms (i.e. avolition (-), memory and attention deficits (c)), have
been caused by abnormalities in the glutamatergic system. These symptoms may be
relieved by the oral administration of D-serine supplements 12 in addition to standard
antipsychotic medication (which mostly mitigate positive symptoms, i.e. auditory
hallucinations).
Given that NMDA hypo-functionality has been associated with schizophrenia, 40 the use
of D-Ser, and other agonists that bind to the same receptor site has been investigated as a
safer alternative to the administration of glutamate, which could cause neurotoxicity.5,13-15
Other amino acid supplements, including glycine and D-cycloserine, enable
improvements in negative and cognitive symptoms induced by glutamatergic
dysfunction.5,16-17 When compared to these amino acids, D-Ser is known to be a full
agonist and provides selective action on NMDA-glycine sites, suggesting that it is the
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dominant endogenous co-agonist of NMDA receptors.18-22 While the academic literature
investigating the role of glycine is extensive, there has been an increasing interest in
investigating the contribution of D-Ser as a therapeutic agent in schizophrenia.
Furthermore, it is evident that the distribution of D-Ser parallels that of the NMDA
receptors more closely than glycine, 23 and it crosses the blood-brain-barrier more
readily.24 Taken together, these reports elucidate the important role of D-Ser and its
applicability to adjuvant treatment of the negative and cognitive symptoms of
schizophrenia. Ultimately, MRS measurements of Ser could provide information on the
inter-individual variability of this metabolite in the living human brain and its possible
abnormal levels in schizophrenia. In the longer term, detection of human brain Ser could
be used as a potential diagnostic marker, as part of tools to properly stratify participants
of drug trials likely to respond to glutamate-modulating therapies. This process of
stratification could also be a key part of personalized dose titration for D-serine oral
supplements, attempting to reach a particular brain dose in the context of a variable
ability to cross the blood brain barrier.
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Figure 3-1. Resonances near the 15 Hz wide region selected by the frequencyselective DANTE RF pulse (simulated FID, 1Hz linewidths).

Previously, the assessment of the endogenous Ser concentration in the human brain has
been impossible using conventional proton Magnetic Resonance Spectroscopy (1H-MRS).
This is mainly due to Ser’s low endogenous concentration at approximately 0.4 -0.8
mmol/kgww (wet weight).25, 45-47 The Ser spectrum consists of multiplets from an ABX
spin system formed by interacting protons from the 2CH and 3CH2 groups featuring
resonances at 3.83, 3.94 and 3.98 ppm, respectively.25 The spectral overlap with the
methylene resonance of creatine (Cr) at 3.92 ppm also makes Ser a challenge to quantify
in humans. Although, the Cr resonance is the most difficult source of Ser signal
contamination to overcome, measurements of Ser are further hindered by overlap with the
neighbouring multiplets of glutamate (Glu) (at ~3.74 ppm) and glutamine (Gln) (at ~3.75
ppm) and possibly small contributions from ethanolamine (Eth) (at ~3.82 ppm) and
phosphoryl ethanolamine (PEth) (at ~3.98 ppm), as illustrated in Figure 3-1.

57

Recently developed techniques in metabolite-selective 1H-MRS of the human brain have
offered promising approaches to producing reliable measurements of brain metabolites
important in neuropsychiatry research. Most recently, developing a method through the
insertion of triple- or quadruple-DANTE frequency selective pulses to an adiabatic
PRESS sequence has allowed the group of Choi et al. to measure in vivo data consisting
of certain metabolites, including Myo-Inositol, Glu and Gln, while eliminating any
spectral conflict from the neighbouring metabolites.26, 27 A recent study by Choi et al. has
been devoted to detecting in vivo brain Ser levels from the frontal region of healthy
subjects by utilizing an advanced proton magnetic resonance spectroscopy (1H-MRS)
method at a field strength of 7.0 T.28 The Choi et al. study includes the implementation of
a constant-TE, triple-refocusing, difference-editing strategy, which involves the collection
of two interleaved datasets, retaining only the signals affected by the editing pulses. This
technique requires the subtraction of a pair of sub spectra acquired with dissimilar sets of
optimized sub echo times (i.e., TE1, TE2 and TE3) which preserves the Ser signal at the
CH2 multiplet by eliminating the interfering Cr singlet at 3.92 ppm. A limitation of this
filtering strategy may include minor subtraction errors that may cause the contribution of
the contaminants in interfering with Ser measurements by up to 30% 28. The subtraction
of the two sub spectra may also produce a reduction in the SNR of the Ser measurements.
Prior to that project, our research group had developed an analogous technique to that of
their previous work and was able to measure low in vivo concentrations of Ser using a
single-shot technique on a Varian Unity Inova 4.0 Tesla system.29
This project proposes the first attempt to measure endogenous brain Ser levels using a 3.0
T clinical Siemens Biograph mMR scanner. To achieve very selective excitation, a noninvasive spectrally selective novel method known as DANTE-PRESS or D-PRESS 29, 30
was developed based on similar principles used in the Choi et al studies 26, 27 with a few
key differences, such as use of single-DANTE pulses rather than triple- and quadrupleDANTE pulses, and the use of a double spin echo rather than a triple spin echo sequence.
The D-PRESS technique was implemented by incorporating a very frequency-selective
single-DANTE pulse to a symmetrical PRESS sequence, placed between the two sliceselective refocusing 180° RF pulses (Figure 3-2).
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Figure 3-2. A sequence diagram of the DANTE-PRESS sequence, together with the
timing and order of the slice selective gradients (Gx, Gy, Gz), the frequency selective
pulses (RF) and the ADC axis.

The Ser resonance at 3.83 ppm has the least amount of contamination from other
interfering metabolites, making it the ideal target for selective excitation. This manuscript
aimed to determine the test-retest reliability of assessments of Ser concentration with DPRESS in in vitro using a series of phantom experiments. The optimized technique was
then utilized to obtain in vivo proof-of-concept data focusing on measurements of Ser
concentration in the frontal brain (left anterior cingulate) of healthy participants, a region
of relevance to future applications in psychiatric disorders.31, 32
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3.2

Materials and Methods:

3.2.1 Phantoms:
Brain-mimicking phantoms were constructed to examine the ability of the metabolite
selective MRS technique in 1) isolating the signal of interest, 2) testing for linearity and
3) determining accuracy and precision of Ser detection. Overall, twelve phantoms were
built and their information is summarized in table 3-1. The phantoms consisted of hollow
polyethylene spheres (diameter (Dia.) [i.d.] ~5, ~7.5 or ~10 cm) filled with buffered
saline (Milli-Q water; 10% phosphate-buffered saline (PBS); pH 7.31; 0.05% sodium
azide (NaN3), to prevent bacterial growth overtime).41 A phantom (Phantom 3) with a
high concentration of Ser (30 mM; S5386-25G; Pcode: 014K06342; Sigma-Aldrich) and
in vivo level Cr (7.5 mM; C0780-50G; Pcode: 101101933; Sigma-Aldrich) was
constructed in order to investigate the J-modulation of the Ser signal acquired at various
echo times and with or without the application of the metabolite-selective RF pulse. Four
brain-mimicking spherical phantoms (Phantoms 4,5,6 and 7, respectively, inner diameters
(Dia.) [i.d.] ~10 cm and ~5 cm) were constructed containing a high concentration of Ser
(30 mM), Cr (25 mM), Glu (30mM; 49449-100G; Pcode: 101097293; Sigma-Aldrich),
and Gln (30mM; 49419-25G; Pcode: 101095200; Sigma-Aldrich) with in vivo
concentration N-Acetylaspartic acid (NAA) (8mM, EO03308AO, Sigma-Aldrich) were
used in order to develop the templates for in vivo data quantification. These separate
phantoms were built to also assess the level of contamination from these neighbouring
signals and Ser signal isolation. Phantoms (Phantoms 4, 8, 9, 10, 11 and 12, respectively)
including serially decreasing Ser levels (30 mM, 20 mM, 10 mM, 5 mM, 2.5 mM, and
1.25 mM) were used to calculate the calibration factor for the measured concentrations.
Preliminary in vitro measurements were obtained in order to develop prior knowledge of
the spectral signature of Ser. Two phantoms (Phantoms 1 and 2) containing in vivo
(~0.732 mM) and double in vivo (~1.464 mM) Ser concentrations were used to assess the
test-retest reliability of the MRS protocol in measuring Ser.

60

Table 3-1. A summary of all the brain-mimicking phantoms that were built for this
study is presented.
Phantom No.

Chemical component

C oncentrations (mM)

Sphere Dia

Product No.

1

DL-Serine (Ser)
Creatine (Cr)
N-Acetyl-L-Aspartic Acid (NAA)

0.732 mM
7.5 mM
8 mM

3.937″

S5386-25G
C0780-50G
44,154-6

2

DL-Serine (Ser)
Creatine (Cr)
N-Acetyl-L-Aspartic Acid (NAA)

1.464 mM
7.5 mM
8 mM

3.937″

S5386 -25G
C0780-50G
44,154-6

3

DL-Serine (Ser)
Creatine (Cr)

30 mM
7.5 mM

3.937″

S5386-25G
C0780-50G

4

DL-Serine (Ser)
N-Acetyl-L-Aspartic Acid (NAA)
3-(Trimethylsilyl)-1-propanesulfonic acid (TPS)

30 mM
8 mM

3.937″

S5386-25G
44,154-6

1 mM

17,883-7

5

Creatine (Cr)
N-Acetyl-L-Aspartic Acid (NAA)

25 mM
8 mM

3.937″

C0780-50G
44,154-6

6

L-Glutamic acid (Glu)
N-Acetyl-L-Aspartic Acid (NAA)

30 mM
8 mM

1.969″

49449-100G
44,154-6

7

L-Glutamine (Gln)
N-Acetyl-L-Aspartic Acid (NAA)

30 mM
8 mM

1.969″

49419-25G
44,154-6

8

DL- Serine (Ser)
3-(Trimethylsilyl)-1-propanesulfonic acid, sodium salt (TPS)

20 mM

2.9530″

S5386-25G

DL- Serine (Ser)
3-(Trimethylsilyl)-1-propanesulfonic acid, sodium salt (TPS)

10 mM

DL- Serine (Ser)
3-(Trimethylsilyl)-1-propanesulfonic acid, sodium salt (TPS)

5 mM

DL- Serine (Ser)
3-(Trimethylsilyl)-1-propanesulfonic acid , sodium salt (TPS)

2.5 mM

DL- Serine (Ser)
3-(Trimethylsilyl)-1-propanesulfonic acid, sodium salt (TPS)

1.25 mM

9

10

11

12

1 mM

17,883-7
2.9530″

1 mM

17,883-7
2.9530″

1 mM

S5386-25G
17,883-7

2.9530″

1 mM

1 mM

S5386-25G

S5386-25G
17,883-7

2.9530″

S5386-25G
17,883-7
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3.2.2 Human participants:
As part of proof-of-concept application to measurements of endogenous levels of Ser in
the human brain, four healthy volunteers (3 males, aged 24, 27 and 33 years, 1 female,
aged 22 years) were recruited and Ser D-PRESS measurements were obtained twice, one
week apart (except for the female participant; subject 1). Typically the periods for the
onset of schizophrenia begin in the early adulthood or emerge in late adolescence;
therefore, the ages of the participants make them appropriate subjects to compare to
individuals with schizophrenia in a future study. All subjects gave written informed
consent prior to the scan. The study was approved by the Health Sciences Research Ethics
Board (HSREB), HSREB file number: 6319, of the University of Western Ontario.

3.2.3 Measurements:
MR examinations were performed on a clinical 3.0 T whole-body scanner (Siemens
Biograph mMR scanner, a dual-modality PET/MRI imaging system 55,56 , St. Joseph’s
hospital, London, Canada) using a standard Siemens 32-channel head coil whose plug
configuration was adapted to this scanner. We implemented a D-PRESS pulse sequence
on the 3.0 T scanner in an similar fashion to what our group previously implemented on a
4.0 T scanner.29 The PRESS sequence is composed of an excitation 90° RF pulse
(hamming filtered sinc; experimentally determined time-bandwidth product (R) for
excitation: 8.750, duration of 2600 s) and two refocusing 180° RF pulses (Mao
refocusing pulses 53, 54; experimentally determined R = 6.000, duration of 7200 s)
supplied in an external file. The D-PRESS pulse sequence inserts a high frequencyselective single-DANTE pulse within the standard symmetrical PRESS sequence at the
midpoint between the two 180o refocusing pulses of the PRESS sequence. The basic pulse
sequence structure is 90-TE/4-180-TE/4-DANTE-TE/4-180-TE/4 and the full pulse
sequence diagram is presented in Figure 3-2. The 180o DANTE pulse (duration of 118.54
ms) comprises a series of short square RF pulses 0.086 ms in duration separated by a
fixed delay of 4.48 ms which produces a frequency profile with a predictable repeating
pattern of narrow passbands. The exact shape of the DANTE pulse is generated at runtime (online) by the pulse sequence in response to the parameters entered in the scanner
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user interface (center frequency, passband full-width-at-half-maximum (FWHM) of 15
Hz, repeating at every 223 Hz intervals (the Frequency Domain Period (FDP)) and is
amplitude-modulated with a Gaussian envelope (truncated at 5%), frequency domain
FWHM = 14000 Hz). For this work, an FDP of 233 Hz was selected to ensure that the
frequency difference between repeating passbands would be equal to the frequency
difference between the Ser 3.83 ppm resonance and the NAA 2.01 ppm singlet. NAA was
used as a reference peak to aid in phasing of the spectrum during post-processing as well
as with the constraining of the spectral quantification template. Figure 3-3 represents the
DANTE pulse used as well as its corresponding frequency profile estimated by its Fourier
Transform.
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Figure 3-3. DANTE RF Pulse amplitude waveform in the time domain (top) and the
corresponding frequency profile obtained by Fourier Transformation (bottom).
DANTE pulse parameters were: passband width = 15 Hz; FDP = 223 Hz; number of
points = 2560; Frequency Domain FWHM = 14000 Hz; amplitude modulation =
Gaussian; amplitude modulation cut-off threshold = 5%.
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A long echo time (286 ms) was used in these experiments since the DANTE-RF pulse’s
bandwidth of 15 Hz (duration of 118.54 ms), which was approximately equivalent to 0.11
ppm, was sufficient to isolate the resonance of serine at 3.83 ppm at 3.0 T. A clinically
acceptable timeframe of approximately eight minutes was used to achieve a reasonable
SNR due to the implementation of a long DANTE-RF pulse. Since the Ser signal
intensity was susceptible to field drifts under the narrow band highly frequency-selective
RF pulse during data acquisition, mainly produced by hardware imperfections, an
assessment of scanner drift effects was performed for a scanning period of ~20 min. In
order to minimize this effect, a parameter was implemented that compensates for
frequency-drifts by enabling the movement of the passband of the DANTE RF pulse in
the direction of the drift depending on its rate of movement during each experiment. The
center frequency of the DANTE pulse was determined at run-time as 1.81 ppm downfield
from the frequency measured for the NAA CH3 peak in a spectrum acquired with a
traditional PRESS acquisition (D-PRESS with the DANTE pulse OFF, TR = 2.0 s, TE =
286 ms, NA = 64). Spoiling gradient pairs along each of the three axes were applied
immediately before and after the DANTE RF pulse to ensure the elimination of any
unwanted signals outside the DANTE passbands. Water suppression was achieved
through a WET water saturation module consisting of three variable flip angle RF pulses
with 17.9 ms duration and Gaussian shape flanked by spoiler gradients.37 An effective
water suppression can be achieved with the DANTE-ON application since it eliminates
any remaining water residuals and only refocuses signals that are affected by all of the RF
pulses. The gradient scheme (including water suppression gradients) was kept constant in
all acquisitions to maintain comparable lineshapes between acquisitions. Prior to
acquiring data, the gradient crushers of this sequence were optimized in order to eliminate
any unwanted coherences (see Appendix C). The main Ser data was acquired with the
DANTE pulse ON (TR/TE = 2.000/286 ms; NA = 256; FDFWHM = 14000 Hz, 4 dummy
scans; sampling points = 2048; phase cycling = 8-step). In order to provide a
concentration reference (other than internal NAA), two separate water-unsuppressed
acquisitions were obtained with the same echo and repetition time as the DANTE ON
acquisition (TR/TE = 2000/286 ms), with (the DANTE frequency centered on water;
FWHM = 15 Hz; NA = 8) and without the DANTE pulse application (NA = 8).
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The separate DANTE-ON water-unsuppressed spectrum was obtained by setting the
DANTE-RF pulse frequency centered on water and used for the correction of eddy
currents in phantom experiments. A Lorentzian eddy current correction technique was
used to eliminate lineshape distortions. Spectra and metabolite concentrations were
quantified using Fitman (locally developed spectral fitting software) 33, a time-domain
fitting algorithm. In order to evaluate reproducibility for the in vitro measurements,
coefficients of variation (CV) were computed and the results were also analyzed
statistically using one-way ANOVA using SPSS v.24 (IBM Corp, Armonk, New York,
USA), respectively.

3.2.4 Experimental:
Phantom experiments:
In order to develop prior knowledge of the spectral signature of Ser, preliminary in vitro
measurements were obtained. In vitro data was obtained from phantom 3 (buffered saline,
inner diameter [i.d.] ~10 cm, pH 7.31) including a “high” concentration of Ser (30 mM)
and Cr (7.5 mM). The data also demonstrates the ability to separate the Ser signal from
the Cr singlet at 3.92 ppm. Considering that Ser consists of an ABX spin system and the
DANTE pulse that was applied only to the X spins (compare Figure 3-4’s top and bottom
traces).
In order to determine the linearity of Ser measurements with DANTE-PRESS, spectra
were obtained from a series of Ser-only phantoms (Phantoms 4, 8, 9, 10, 11 and 12,
respectively) with the following concentrations: 30 mM, 20 mM, 10 mM, 5 mM, 2.5 mM,
and 1.25 mM. This data was also used to determine the effective number of protons
participating to the DANTE-PRESS Ser signal. With a standard PRESS spectrum, one
would assume the total Ser signal to originate from three protons, but the Gaussian
passband over the 3.83 ppm Ser resonance, although consistent, does not provide a flat
inversion profile over the range of resonances associated with the X spin of Ser. The
effective number of protons must therefore be determined empirically from the slope of
the linearity curve linking measured and known concentrations (Figure 3-5).

66

In order to determine the accuracy and precision of Ser measurements in phantoms, ten
consecutive DANTE-PRESS spectra were obtained from within-session at baseline (no
phantom repositioning, with different scanning adjustments) and between-session from
the same phantom scanned a week later. For accurate adjustments of measurement
parameters, additional tuning and manual adjustments of frequency, first- and secondorder shim coils and water suppression were performed prior to each in vitro
spectroscopy measurement. Two phantoms (Phantoms 1 and 2) containing either “in
vivo” [~0.732 mM] or “double in vivo” [~1.464 mM] Ser concentrations were scanned
during each session. Each phantom contained in vivo level Cr [~7.5 mM]. The results
were interpreted and reported using descriptive statistics (means, standard deviations
(SDs), and CVs) and any difference in the means of the unpaired measurements were
assessed using a classical statistical method, one-way analysis of variance (ANOVA).
Prior knowledge of metabolite spectral signatures for Ser (30 mM), Cr (25 mM), Glu (30
mM), Gln (30 mM) and NAA(8 mM) were obtained from aqueous phantoms (Phantoms
4,5,6 and 7, respectively) prepared as above. NAA’s CH3 singlet was used as a chemical
shift reference for all phantoms. Spectral quantification templates for in vivo data were
formed from the combination of spectral signatures for the five metabolites (Ser, Cr, Glu,
Gln, and Naa). The resulting spectra were used to construct a Ser quantification template
consisting of 32 resonances and 5 metabolites constrained according to chemical shift,
linewidth and phase (0th and 1st order). Each metabolite had a single amplitude parameter
associated with its spectral signature.
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Figure 3-4. Spectra obtained from a phantom containing 30 mM of Ser and 7.5
mM of Cr, using an echo time of 286 ms with D-PRESS (top) and symmetrical
PRESS with an echo time of 286 ms (bottom).
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Figure 3-5. A series of phantoms with the following concentrations of serine were
scanned: 20 mM, 10 mM, 5 mM, 2.5 mM, and 1.25 mM. A linear relationship
between measured and known concentrations was confirmed (r2 =0.9995, (p-value <
0.001))
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In vivo experiments:
To demonstrate the applicability of the D-PRESS technique for in vivo Ser measurements
in the healthy human brain, measurements were obtained from a single voxel (20x20x20
mm3) (Figure 3-6) positioned in the left anterior cingulate’s most rostral portion using
1

mm isotropic 3D MP-RAGE images for guidance (TR/TE/TI = 2000/2.98/900 ms; flip

angle = 9°; field of view = 256×256×176 mm3; 176 slices; slice thickness = 1.00 mm).

Figure 3-6. This figure illustrates the voxel (20 × 20 × 20 mm3) positioning in the left
anterior cingulate in a healthy participant.

It was essential to use a careful voxel localization on repeat scans to reduce the amount of
variability in concentration measurements. Accurate voxel re-localization was achieved
by identifying local anatomical landmarks 43, 44 and using high resolution images 42 to
ensure reproducible voxel positioning between sessions. Voxel localization was achieved
by mainly using the midsaggital image and by placing the voxel in the pregenual anterior
cingulate cortex (anterior to the genu of the corpus callosum) 51 with its inferior border
located along the plane of the anterior-posterior commissure line.52 The voxel of interest
was placed on the brain region which was dominated by gray matter (GM). Therefore, the
tissue compositions of GM, white matter (WM), and cerebrospinal fluids (CSF) often
used for correcting the water signal for tissue water content were not taken into
consideration during metabolite quantification. Nevertheless, a tissue water content of
81% was assumed for all in vivo scans (i.e. 100% grey matter content was assumed).
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The D-PRESS pulse sequence used the same parameters as those used in phantom
experiments (DANTE passbands = 15 Hz (0.11ppm), amplitude modulation = Gaussian,
FDP = 223 Hz, FDFWHM = 14000 Hz, TR/TE = 2000/286 ms; 4 dummy scans;
sampling points = 2048; NA = 256; phase cycling = 8-step). These participants underwent
two examinations seven days apart and two consecutive spectra were obtained at each
session (within-session), except for the one female participant (subject 1). The First- and
second-order shims were adjusted manually. The final in vivo template included the
individual resonances of a total number of five metabolites (Ser, Cr, Glu, Gln and NAA),
which were modeled and constrained. The time-domain iterative fitting algorithm used a
tolerance value of 0.0001 that specified the percentage change in chi squared value which
must have been achieved before the fit was considered completed. The minimum and
maximum numbers of iterations were set to 50 and 5000 for both in vitro and in vivo
templates respectively, the convergence criteria were usually met by the time 500
iterations were completed. The iterative fitting procedure was seeded with initial
conditions and constraints to guide its convergence until the residuals of fit were
minimized. The model contained peak parameters amplitude for each metabolite, with
one parameter for chemical shift, Lorentzian width, zero-order phase, and delay time part
of the quantification template.33 There were a total number of five metabolite spectral
signatures included in the template and the peaks from each spectral signature would
change in amplitude together (grouped by amplitude constraints), but separate from the
amplitude of other metabolites. Thus, a total number of nine fit parameters were
implemented in the constraint file that were interpreted by the fitman fitting routine.

3.3

Results:

In a phantom solution (Phantom 3) containing a high level of Ser (30 mM) and in vivo
concentration of Cr (7.5 mM), we demonstrated that the AB spin resonances of Ser
displayed a J-coupling pattern acquired with D-PRESS (DANTE pulse ON) resonances
were similar to those resonances acquired with a symmetrical PRESS sequence (DANTE
pulse OFF) at the same echo time of 286 ms (see Figure 3-4). It can be gleaned from
Figure 3-4 that Ser MRS spectra can be obtained without significant interference from the
3.92 ppm Cr resonances, which can be successfully suppressed.
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Representative in vitro test-retest spectra are displayed in Figure 3-7. The in vitro spectra
of Ser presents two vertical solid lines (A, B) that indicate the range of Ser resonances
that were quantified and a single vertical dashed line (C) specifying the small residual
signal produced from the Cr peak located at 3.92 ppm. In the in vitro experiments, this
narrow-band frequency-selective technique enabled the suppression of the main
confounding peak arising from a Cr singlet at 3.92 ppm (suppression factor ranging
between 97% to 99% for the “in vivo” phantom and 99% on average for the “double in
vivo” range experiments). As illustrated in Figure 3-7, there is an apparent systematic
effect for these ten repeated acquisitions: the residuals of Cr signal increases as the scan
number increases and this may be caused by the scanner drifts. The amount of drift was
below detectible, so the acquisitions were used without correction. Some residual drift is
nevertheless observable in the final spectra. Figure 3-8 indicates in vitro demonstration of
ten repeated measurements that were obtained from “in vivo” (~0.732 mM) concentration
phantom and from the “double in vivo” (~1.464 mM) concentration in two scanning
sessions occurring one week apart. One-week repeat average concentration of the
phantoms containing “in vivo” and “double in vivo” Ser concentrations at baseline were
1.13 ± 0.09 and 2.18 ± 0.13, and one-week apart were 1.06 ± 0.10 and 2.23 ± 0.14,
respectively. The differences of the mean values were compared between sessions by
conducting one-way ANOVA analysis and no statistically significant differences in the
values were found for the in vivo (F = 2.790, df =18, p = 0.112) and double in vivo (F =
0.595, df =18, p = 0.452) measurements. The resulting coefficients of variation were low
for both the in vivo (CV in the range of ~8-9%) and double in vivo (CV in the range of
~5-6%) measurements, demonstrating sufficient repeatability to warrant in vitro MRS
measurements.
To assess whether field drifts can degrade the frequency calibrations, as confirmed by the
measurements obtained from the water resonance with the DANTE application from
phantom experiments, scanner drifts were monitored for a scanning period of ~20 min.
The results indicated that, for that timeframe, the signal loss of the water peak is
negligible due to this hardware imperfection (Signal loss < 1%, as verified in phantom
experiments).
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The average linewidth, full width at half maximum (FWHM), of the in vivo unsuppressed
water signal was ~13 ±2 Hz at the echo time of 286 ms, after performing the first-order
and second-order shimming adjustments. The in vivo spectra of Ser obtained with the
DANTE application compares favorably with the spectrum obtained in in vitro, as
illustrated in Figure 3-9. A stack of in vivo D-PRESS serine spectra obtained from the left
anterior cingulate of three healthy participants, together with the standard PRESS
spectrum acquired from subject 1, are presented in Figure 3-10. The signal near 3.83 ppm
ascribes predominantly to the X spin system of Ser and some residual signal from the Cr
peak at 3.92 ppm. As demonstrated in Figure 3-10, for the in vivo experiments a
suppression factor of 4 (~75%) to 8 (~90%) was achieved to almost completely eliminate
the Cr signal introduced from resonances at 3.92 ppm. This figure also illustrates the
signals from additional potential contaminants from the neighbouring metabolites,
including Gln and Glu, which were suppressed (as demonstrated in in vitro
measurements) by average factors of approximately 3 (~67%) and 4 (~75%), respectively.
Figure 3-11 displays an example of spectral fitting results, illustrating the data, the fitting
line, the fit components, and the fit residuals. The addition of these metabolites’ spectral
signatures in the quantification template results in lower fit residuals and thus reduces
variability of Ser measurements by taking these sources of contaminations into
consideration.
The reproducibility of MRS measurements greatly depends on the quality and
reproducibility of RF excitation parameter adjustments and availability of more advanced
MRS adjustment capabilities, as illustrated in the MRS literature.34 Therefore, the
DANTE-PRESS sequence was further modified to implement inline adjustment
capabilities. This enabled the optimization of several parameters of the pulse sequence,
including fine-tuning of the frequency offset of the DANTE pulse and fine adjustments of
the transmitter voltage of the RF pulses (Figures 3-12 and 3-13).
The calibration of these parameters and the use of advanced adjustments in each
individual are essential to minimizing the degradation of spectral quality and signal loss.
The optimization of the selected parameters was accomplished by using real-time
monitoring of the measurements prior to the start of the data acquisition. In order to
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generate proper pulse sequence profiles, the optimum flip angle values (for the excitation
and the two refocusing RF pulses, concurrently) were determined at the beginning of each
scanning session. To arrive at the final desired D-PRESS sequence functionality, the fine
tuning of the adjustment of the frequency offset of the DANTE RF pulse was performed
prior to obtaining each Ser-selected spectra. This is a critical step since any
misadjustments in computing the DANTE-RF frequency offset cause significant signal
loss and the proper fitting of the developed in vivo template for quantification is
jeopardized.
The following MRS ratio of metabolite peaks of Ser to NAA and Ser to Cr were
computed. MRS ratio concentrations were obtained from all of the healthy participants
whose spectra are presented in Figure 3-10. Assuming identical relaxation times, the
concentrations of the D-PRESS Ser and PRESS NAA signals obtained from the three
healthy participants were compared, and the Ser-to-NAA concentration ratio was
estimated to be 0.09 ± 0.01 (mean ± SD, n = 5). This ratio is greater than the expected
values (by ~32%, considering Ser 0.732 mM and NAA 10.3 mM) when compared to the
findings in the literature.25, 45-49 The ratios of Ser-to-Cr were also obtained and the values
were 0.20 ± 0.03 (mean ± SD, n = 5), higher (by ~38%, considering Ser 0.732 mM and Cr
5.1 mM) than the estimations provided in the published studies.25, 45-50 Prior to
implementing the inline adjustment technique, two repeated measurements from the firstand second-in vivo experiments (two male subjects; participant 2 and participant 4) were
quantified. The MRS ratios of these measurements are presented in table 3-2. Although it
is too early to draw firm conclusions regarding the in vivo data, inline adjustment
capabilities appear to enhance the reproducibility of Ser in vivo measurements.
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Table 3-2. MRS ratio summary * of all of the in vivo measurements are displayed.
For all of the subjects, except subject 1, a second measurement was obtained within
the same day. Pre adjustments include the measurements obtained prior to
implementing the inline adjustment properties to the sequence.
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Figure 3-7. These spectra illustrate the 10 consecutive in vitro D-PRESS
measurements obtained from two phantoms that contain in vivo serine
concentrations and double in vivo serine concentrations, illustrated at the left
and the right of the figure, respectively, at baseline & one week apart (indicated
as SCAN 1 and SCAN 2, respectively). The two vertical solid lines (A, B)
demonstrate the spectral width for Ser resonances and the Cr residuals
generated from the peak at 3.92 ppm are indicated by the single vertical dashed
line (C).
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Figure 3-8. The average value of baseline in vivo & one week (Week 1 and
Week 2) plus baseline double in vivo & one week (*Week 1 and *Week 2)
were 1.13 ± 0.09 (CV = 8.3%), 1.06 ± 0.10 (CV = 9.9%), 2.18 ± 0.13 (CV =
5.7%) and 2.23 ± 0.14 (CV = 6.5%), respectively.
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Figure 3-9. PRESS (A, C) and DANTE-PRESS (B, D) spectra (TE = 286 ms,
TR = 2.0 s) were obtained from the anterior cingulate (A, B) and in vitro
data acquired from a phantom composed of a solution of Ser and Cr
(C, D). A LW correction factor of 2 Hz was applied to all of the four spectra.
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Figure 3-10 . A stack of in vivo DANTE-PRESS spectra obtained
at TE=286 ms from the left anterior cingulate of three healthy
participants. Two consecutive data-set were obtained within the
same session from participants 2 and 3. The bottom trace is a
standard PRESS spectrum obtained at TE=286 ms from
participant 1.
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Figure 3-11. Representative of an in vivo spectrum. Line (A) represents
the data in black and the fitting line in red, lines (B and C) illustrate
the fitting components of serine in orange and creatine in purple, lines
(D and E) represent the fitting components of glutamate in green and
glutamine in pink, respectively. Line (F) shows the residuals in
blue (data minus fit). LW correction factor of 2 Hz was applied.
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Figure 3-12. The “Special Card” illustrates the parameters which interact with the
DANTE RF Pulse. The optimization of the DANTE frequency adjustments and the
RF flip angle values are enabled through the use of this card.
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Figure 3-13. The inline display illustrates the DANTE RF pulse’s chemical shift
(CShift) value, the repetition number (REP), the signal value (Signal), and highlights
the maximum value (MaxValue*) with a purple label.
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3.4

Discussion:

This study demonstrated the first investigation of the reliability of the DANTE-PRESS
method to detect in vitro Ser using a metabolite-selective single-voxel 1H-MRS technique
on a 3.0 Tesla clinical scanner. We evaluated the accuracy and precision of the
measurements obtained in phantoms containing human brain mimicking concentration
levels of Ser. This advanced 1H-MRS technique, D-PRESS, is capable of isolating the
resonances of Ser by significantly suppressing the resonances of Cr originating at 3.92
ppm and eliminating other interfering metabolites of Glu at ~3.74 ppm and Gln at ~3.75
ppm.
This study reports only the MRS ratio concentrations of Ser to other metabolites because
of factors that make it difficult to compare the absolute numbers. The absolute values of
NAA and Ser separately may vary significantly from scan to scan due to the voltage
adjustments that were performed at the start of each scanning session in turn prior to each
data acquisition. To investigate the absolute concentration, future studies may be able to
take full advantage of voltage adjustments in obtaining higher SNR values by correcting
the flip angle values based on the voltages.
A limitation of this report was that it did not incorporate the contributions from PEth and
Eth metabolites, whose resonances may be refocused by the frequency-selective DANTERF pulse into the final quantification in vivo template. The Fitman program used for
quantification applies the Levenberg-Marquardt minimization algorithm, an automated
fitting procedure, which may result in quantification errors if certain metabolites are not
included in the prior knowledge. The fitting procedure tends to compensate for the
missing peaks by increasing or decreasing existing components of the fit, which may
result in an over- or under-estimation of Ser signals. Therefore, in future studies, for a
more precise quantification, it is critical to include all the neighbouring metabolites in the
prior knowledge in order to assess the level of contamination and its effect on the
concentrations of Ser.
A long, 118.54 ms DANTE pulse with a Gaussian waveform (5.0 % amplitude cut-off)
was used to obtain a narrow refocusing bandwidth of 15 Hz. At field strength of 3.0
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Tesla, the 15 Hertz bandwidth ensured significant suppression of the interfering singlet of
Cr at 3.92 ppm and allowed for the detection of Ser. The use of a long echo time (TE =
286 ms) in these experiments was necessary to accommodate the long DANTE pulse.
This can be a disadvantage of this method due to the associated substantial signal decay
via transverse relaxation effects. On the other hand, it has been noted that
macromolecular (MM) resonances are abundantly present at 4.00 ppm, near the Ser
resonances at 3.83 ppm 35, 36 and their contribution to Ser signals is completely eliminated
at such long echo times.
Despite the scanner drift that arises from hardware imperfections, including changes in
the temperature over time and long scanning duration, the signal intensity and line shape
of Ser obtained using the narrow-band 180° DANTE RF pulse still generates an
acceptable signal-to-noise ratio for this low concentration metabolite. Nonetheless, the
implementation of the extremely narrow radiofrequency RF pulse of DANTE (at a long
echo time of 286 ms) is still susceptible to hardware-related frequency drift and
restriction of participant head movement is critical to avoid motion-related frequency
drifts.39
In conclusion, this novel metabolite-selective 1H-MRS method, dubbed D-PRESS, was
the first attempt to measure endogenous human brain Ser levels at field strength of 3.0
Tesla. Results suggest in vivo-like concentrations of Ser can be measured reliably with
little contamination from other metabolites. The implementation of inline adjustment
capabilities to this custom D-PRESS 1H-MRS sequence seemed critical to achieve
reproducible Ser measurements in vitro and in vivo. Together the low CV values and the
results obtained from the one-way ANOVA analysis for the in vitro findings suggest that
the DANTE-PRESS sequence was capable of successfully detecting the signal of in vitro
Ser with sufficient reproducibility and precision to justify assessment of test-retest
reliability of endogenous in vivo levels. The proof-of-concept in vivo data showed that the
technique is applicable to in vivo measurements. Further studies need to be performed in
order to determine the reproducibility of these measurements in healthy controls and
schizophrenic patients.
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Chapter 4

4

Thesis summary:

In recent years, there has been a growing academic interest in in vivo detection of serine
(Ser) concentrations in the human brain as our group, and other researchers, have
investigated its significance and relevance to neuropsychiatric disorders.1 Ser
concentrations have been implicated in the pathophysiology of schizophrenia by a
number of research findings.2 Evidence suggests that alterations in the NMDA receptor,
which causes glutamatergic abnormalities, are the main explanation for the negative and
cognitive symptoms of schizophrenia, which may respond to the oral administration of Dserine supplements.3 The detection of the naturally occurring brain levels of serine has
been impossible using standard proton Magnetic Resonance Spectroscopy (1H-MRS), due
to its comparatively weak signals, and neighboring strong signals. Advanced 1H-MRS
methods conducted at non-clinical, high-field strengths of 4.0 Tesla (T) 4 and 7.0 T, 5 have
been capable of measuring the endogenous levels of human brain serine. Nonetheless, no
earlier research has employed these techniques at the more widely available clinical field
strength of 3.0 T.
In summary, this thesis has introduced an innovative 1H-MRS DANTE-PRESS (DPRESS) pulse sequence, implemented by inserting a spectrally-selective single-DANTE
pulse into a standard symmetrical PRESS sequence. D-PRESS is capable of assessing
endogenous levels of Ser by refocusing its signals and greatly suppressing the signals of
other metabolites. D-PRESS uses a narrow radiofrequency pulse centred on a chosen
spectral line of interest (i.e. the X spin of the Ser’s ABX spin system) such that
neighboring resonances remain unaffected. Chapter 3 summarizes findings from the
evaluation of the test-retest reproducibility of Ser measurements in brain-mimicking
phantoms, with two concentrations in the in vivo range. It also presents preliminary in
vivo proof-of-concept data demonstrating the feasibility of Ser measurements at 3.0 T.
Results demonstrated the reliability and reproducibility of Ser measurements obtained in
vitro and suggests readiness for comparable work in vivo.
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4.1

General remarks, limitations and implications:

The remainder of this chapter will highlight some of the advantages of the experimental
protocol presented in this thesis. Despite the effort devoted to developing and
implementing an advanced 1H-MRS sequence in conjunction with MRS adjustment
capabilities (see Appendix A), the following will identify any limitations and deficiencies
in the existing practice that need to be addressed, and discuss ways of improving future
studies.

4.2

The DANTE-PRESS protocol’s advantages and limitations:

4.2.1 Advantages:
The D-PRESS pulse sequence consists of the addition of a frequency-selective, singleDANTE pulse with very narrow passband, into a symmetrical PRESS sequence (adapted
from the MRI vendor’s product PRESS sequence version VB20PSP4). The D-PRESS
sequence introduced in Chapter 2 is capable of selectively exciting only the spins of
interest in a very narrow range of radiofrequencies. Thus, a major advantage of the DPRESS technique is that it offers an enhancement in sensitivity to distinguish proton
signals from metabolites otherwise difficult to detect.6, 7 The selective pulse refocuses a
particular resonance (or a group of resonances) within complex spectra while leaving
adjacent resonances, which may hinder its measurement, unaffected.8 The most important
advantage of the D-PRESS pulse sequence is that its metabolite-selective DANTE pulse
is generated online in response to the user’s input. The pulse sequence allows for online
optimization of a variety of experimental parameters, including the pulse duration of the
DANTE pulse that determines its selectivity, 8 fine adjustments of the spoiler gradients
(i.e. the height and the duration; see Appendix B), the modulation and the truncation
value of the RF pulse (i.e. Gaussian), and the produced inversion-frequency profile of the
pulse in order to achieve an acceptable excitation of a region of an NMR spectrum.9
Indeed, it is essential to select a suitable amplitude modulation function to improve the
shape of the resulting frequency passband of the DANTE RF pulse.10 In this thesis a
Gaussian-modulated DANTE RF pulse was implemented.8 In comparison to a rectangular
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pulse, in most circumstances depending greatly on the selected waveform cut-off for a
Gaussian shaped RF pulse, a Gaussian pulse with the same length generates a narrower
profile.10Although, a rectangular pulse is simpler in terms of implementation, it generates
unwanted side lobes that may lead to refocusing of unwanted resonances.8 A sincmodulated DANTE RF pulse would produce a more square refocusing profile but
requires a longer pulse duration, pushing TE beyond the practical feasibility range.11A
properly truncated, highly selective Gaussian modulation targets a narrow range of the
NMR spectrum and eliminates the refocusing of the neighbouring resonances since its
amplitude declines rapidly in the tails.8 For a detailed description of the user interface
developed as part of this work for the online manipulation of D-PRESS pulse sequence
parameters, see Appendix A.

4.2.2 Limitations and implications:
The implemented single-DANTE pulse allows the production of a frequency-domain
inversion, with a profile repeating at a certain frequency interval (in Hz), which may
cause the excitation of the unwanted metabolites elsewhere in crowded spectra other than
the reference and the metabolite of interest.11 For example, if a sideband of the DANTE
pulse falls near the water peak, the pulse will interfere with water-suppression and the
resulting baseline distortions hinder the detection of metabolites, including serine (the X
spin, 3.83 ppm), near water (~ 4.7 ppm). Another obstacle arises when the difference
between these repeating frequency passbands (a.k.a. Frequency Domain Period, FDP) is
roughly less than 100 Hz, which may cause a reduction in the obtained SNR, as verified
in our experiment. In our experiments, in order to overcome these challenges, we chose a
reference metabolite (i.e. NAA) whose peak position is far away, 1.81 ppm (~ 223 Hz),
relative to the resonance of the metabolite of interest (i.e. serine) within the spectrum of
interest. This practice ensures the full separation of repeating passbands’ profiles.
However, it limits our choices in selecting a suitable reference peak.6 For future work, our
recommendation is to implement a double-DANTE pulse that is capable of simultaneous
excitation of spins, operating in two independent rotating referencing frames.7 The
double-DANTE sequence was first introduced by Green et al. and allows for the
production of two arbitrary frequencies in high-field NMR.7, 11 Not only will the
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background contaminant signals be completely suppressed and only the desired
metabolites will appear on the NMR spectrum, but the SNR value may not be affected
when the frequency difference between passbands of interest is set to less than 100 Hz.

4.3

Biograph mMR PET/MRI 3.0 Tesla scanner:

The 3.0 T Biograph mMR MR-PET system scanner used in this study is an integrated
multi-modal imaging device and may not be representative of all other typical 3.0 T MRIonly scanners (i.e. Siemens’ Verio, Trio, Skyra and Prisma scanners). Aside from the
reduction in the space within the bore of the MRI scanner 60 since the PET photodetectors
are highly sensitive to temperature changes, a redesign of the gradient coils cooling
system was required to monitor changes in heat.61, 62 The installation of the temperature
sensors and the implementation of the liquid cooling approach 63 ensures the system to
gain thermal stability and to operate at lower temperature in comparison to other
conventional MRI systems.61, 63 The effective monitoring of the temperature of the
detectors and the achieved thermal stability presumably aids in the reduction of the
frequency drift. Although no data has been presented, it is possible that the rate of
frequency drift may be more pronounced in other standard clinical 3.0 T scanners which
may interfere with the spectral quality or reduce SNR. The loss in the SNR related to drift
may be mitigated by dynamically adjusting frequency based on a measurement-based
prediction of the drift rate as discussed in Chapter 3.

4.4

Ultra-high magnetic field of 7.0 Tesla versus 3.0 Tesla:

This work presents the first investigation of test-retest of endogenous measurements of
serine at 3.0 T. The implementation of the single-voxel DANTE-PRESS technique on a
clinical platform at 7.0 T relative 3.0 T will allow for a substantial increase in the signal
to noise ratio (SNR) at higher B0, and an enhancement in spectral resolution due to an
improvement in the separation of spectral lines of individual metabolites.13, 14 Since there
will be an increase in the chemical shift dispersion, a higher FHWM value of the DANTE
pulse (~35 Hz) will be required to target the resonance of serine at 3.83 ppm compared to
the FHWM value of 15 Hz used at 3.0 T. Ultimately, due to the reduction in the duration
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of the DANTE pulse (increased bandwidth/FHWM value), the implementation of a
shorter TE value is possible, which in turn may reduce the attenuation of signal caused by
J-coupling effects.12 An increase in B0 up to 7.0 T results in an improvement in the SNR
(approximately 2-fold in comparison to 3.0 T).15 Because of the resulting improvement, a
smaller number of averages can be used to produce an acceptable MRS spectra which will
result in reduced scan time 12 (potentially lessening patient motion effects). Despite
increases in spectral linewidths at 7.0 T 16 compared to 3.0 T, they are outweighed by
increases in spectral dispersion. Increases in spectral dispersion, interestingly, also
contribute to the reduction in the amount of J-dephasing of the NMR spectrum; as the
formerly strongly coupled metabolites become more weakly coupled (chemical shift
difference over J ratio is decreased). This fact will lessen the amount of second-order Jcoupling effects for the AB spins of Ser and will allow for a more precise and reliable
quantification of metabolites with complex spectral signatures.17 Therefore, it is expected
that the use of DANTE-PRESS at ultra-high field will lead to significant improvements in
the detection of metabolites with low concentrations and a strongly coupled spins, 15 such
as serine.
A reasonable path for future work would be to compare the test-retest reliability of invitro and in-vivo Ser measurements obtained at the ultrahigh magnetic field of 7.0 T to
that obtained at 3.0 T. The information would be useful to investigators planning studies
of human brain serine when deciding which field strength to use and evaluating the cohort
size required.

4.5

Caveats and future recommendations:

Some limitations associated with the D-PRESS protocol were presented in Chapter 3.
This MRS technique measures both D-serine and L-serine within a region of interest, and
cannot distinguish these metabolites individually. It also cannot provide information
regarding the d-/l-serine ratio which has been suggested to be a therapeutic marker in
these patients.18 Another important drawback that was not mentioned within Chapter 3
includes the accurate measurements of in vivo metabolite concentration relative to water
concentrations of brain tissues. The calculations of the fractional components of the grey
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matter (GM), white matter (WM), and cerebral spinal fluid (CSF) were not performed.
Water content of GM equals 81% and WM equals 71%, as illustrated in the literature.19
Thus, in future in vivo work, accurate quantification of metabolite concentrations will
need to correct for the fractional tissue content of the MRS volume.

4.6

Future work:

4.6.1 1H-MRS schizophrenia:
As stated before, it has been postulated that glutamatergic deficiency contributes to the
pathophysiology of schizophrenia. Evidence suggests precise and reliable detection of
glutamate (Glu) and glycine (Gly) in the human brain is crucial for research in neuropsychiatric diseases including schizophrenia.20, 21, 22 Glycine, an inhibitory
neurotransmitter, 23 is an essential co-agonist 24 that may facilitate endogenous
glutamatergic transmission by modulating the functional activity of N-methyl-D-aspartate
(NMDA) receptor complex. Although detection of glycine using MRS methods with long
echo times has been reported, 25 the assessment of this metabolite has been difficult due to
its low abundance in the human brain and interference from macromolecules and myoinositol.22 As mentioned in Chapter 1, measurements of glycine in schizophrenic patients
using 1H-MRS techniques have not yet been reported. Abnormalities in glutamate have
been found in patients who suffer from schizophrenia.51 Glutamate quantification has
been challenging due to its complex spectral signature and interferences from the
neighbouring metabolites.26 Metabolic abnormalities of glutamate in schizophrenia have
been investigated by applying a non-invasive standard 1H-MRS and the following will
summarize most of these 1H-MRS findings.
Clinical 1H-MRS studies demonstrated higher than normal levels of glutamine 27 and
glutamate

28

in the anterior cingulate of healthy participants under the influence of an

antagonist known as ketamine. Similarly, elevated levels of glutamate in the
precommissural dorsal-caudate (a dopamine-rich region) 29and in the associative striatum
and the cerebellum; 30 increased levels of Gln/Glu in the AC; 31 elevated levels of
glutamate in the prefrontal cortex and hippocampus; 32 higher levels of GABA and
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glutamate-glutamine (Glx) in the prefrontal cortex 33 of unmedicated, first-episode
patients were observed by applying 1H-MRS. Another group found elevated
concentrations of glutamate in the prefrontal and hippocampal regions in schizophrenic
patients.34
Our group has also been capable of assessing abnormalities in the concentration of
glutamatergic metabolites in these affected individuals by using single voxel 1H-MRS
methods. The following findings were reported by our group: higher glutamine levels in
the AC and thalamus 35 and higher levels of glutamine in the left AC and thalamus 36 were
observed in anti-pscychotic naïve patients; lower levels of glutamate and glutamine and
higher than normal levels of glutamine were found in the left region of AC and the
thalamus 37 respectively in chronic patients. Another group also examined the
concentration levels in glutamine in the medial prefrontal cortex in untreated patients and
have found an increase in the concentration compared to the healthy groups.38 Spectra
obtained from the medial prefrontal cortex from adolescents who are at high genetic risk
for developing schizophrenia have demonstrated a higher glutamate/glutamine
concentration compared to healthy controls.39 Conversely, in a study conducted in twins,
the abnormalities in glutamate concentrations in schizophrenic patients were examined
and their unaffected twins and the levels were found to be significantly lower in both
groups compared to healthy subjects.40 A different report had indicated an increase in
glutamate and glutamine in the white matter portion of the brains of those in an elderly
schizophrenic group.41 More importantly, longitudinal 1H-MRS studies conducted in first
episode patients after treatment have demonstrated the normalization and the reduction of
glutamate levels in the associative striatum and the frontal lobe, respectively.42, 43
Similarly, other reports suggest which medicated first episode patients showed
normalization of levels of GLX and GABA in the prefrontal cortex 44 and clinically
stabilized patients had reduced levels of GLX in the anterior cingulate, 45, 46 supporting
the results obtained by our group previously.37 Findings from a recent meta-analysis 1HMRS study indicate a rise in the medial frontal in Glu/Gln levels in the early stages of the
illness and lower ratios in older patients.47
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The 1H-MRS reports mentioned above provide in vivo information about the glutamate
levels in patients diagnosed with schizophrenia. It is crucial to precisely and reliably
assess the magnitude and extent of alterations in glutamatergic metabolites. These results
indicate the growing appreciation of developing an effective technique, capable of
detecting metabolites with difficult resonance structures at a high degree of precision. As
indicated, the 1H-MRS findings regarding glutamate concentrations have been
inconsistent. A few factors have been proposed that may contribute to these mixed 1HMRS findings, including a variation in glutamate levels due to impaired functional
integrity of the neurons, 48 the severity of the illnesses, the effects of anti-psychotic
medications and methodological reasons.49 The majority of the 1H-MRS studies in terms
of investigating the alterations in glutamate in schizophrenia patients have used magnetic
field strengths lower than 4.0 T.50 Reliable measurements of glutamate concentrations
have been challenging at low magnetic fields, which may have led to the conflicting
research results found in the literature.49 Previous reports examined the reproducibility
and sensitivity of 1H-MRS measurements of glutamate and Glx in healthy subjects and in
schizophrenic patients. The reproducibility of glutamate measures in healthy participants
at 1.5 T and at 3.0 T was assessed. The results indicated a coefficient of variation (CV)
ranging from 11.0 and 13.1% in the ACC and insula at 1.5 T 52 and 13% at 3.0 T.57
Another report indicated coefficients of variation in measurements of glutamate ranging
from 5% to 10% in the cingulate gyrus of healthy participants at 3.0 T.59 Measurements
of glutamate were obtained at 1.5 T from patients with schizophrenia and the CV ranged
from 20-50% 55 in the frontal lobe and 36-44% in the medial temporal lobe.56 1H-MRS
assessment of Glx at 3.0 T in patients with schizophrenia were obtained, and the results
showed a CV range of 15–24% in the frontal and caudate regions.53 Measures of
glutamate provided a CV of approximately 2-3% in the ACC, conducted at 7.0 T.54 Given
the significant findings related to alterations in glutamate concentrations in schizophrenic
patients and poor CVs (at field strengths < 7.0 T), it is crucial to apply more advanced
and robust MRS sequences. DANTE-PRESS, a promising metabolite-selective approach,
is better suited for the reliable and precise quantification of metabolites using low
magnetic field strengths, and might enable achieving a lower CV range (with an estimated
value of < 15% at 3.0 T), in measuring glutamate in patients with schizophrenia.
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Since the D-PRESS technique is capable of improving the quantification of the selected
metabolites by isolating their signals, the next logical step would be to utilize this
technique in order to quantify difficult metabolites implicated in the etiology of
schizophrenia such as glutamate, glutamine and glycine. The work would help develop a
more comprehensive understanding of the neurochemical alterations in schizophrenia in
order to provide design or monitor new treatments. Taken together, these findings suggest
a rationale for investigating the abnormalities in glutamate, glutamine, glycine and serine
with higher precision methods. Longitudinal studies of these metabolies may extend our
knowledge of the pathophysiology of schizophrenia; allow the improvement of treatment
response prediction and categorization of patient cohorts.58 In vivo measurements of
human brain serine, glycine and glutamate in schizophrenia could also allow the
exploration of the possible link between abnormal glutamate levels in schizophrenia and
endogenous activation of the NMDA glycine site.
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Appendix A: DANTE-PRESS (the sequence and the special Card)
The D-PRESS sequence and the user interface for its parameters were developed using
the source code of the MRI scanner manufacturer’s product source as a starting point.
This was provided by, and in collaboration with, Dr. Gerald Moran, from Siemens
Canada under the terms of the Master Research Agreement between Lawson Health
Research Institute and Siemens Canada. As described in Chapter 4, a custom DANTEPRESS pulse sequence was programmed, as well as an associated user interface, allowing
more advanced pulse sequence parameter modification capabilities. The Integrated
Development Environment for Applications (IDEA) provided by the manufacturer is the
pulse programming environment and set proprietary C++ classes that were used to
implement the D-PRESS method, interface and online post-processing capabilities. The
new features of the D-PRESS are included in the “sequence/special” card of the scanner’s
user interface.
DANTE-PRESS parameters:
Once a user clicks on the “DANTE RF Pulse” check box, it adds the DANTE RF Pulse
and its crusher gradients to the standard symmetrical PRESS pulse sequence as the
second refocusing pulse (non-slice selective), transforming this double spin echo
sequence into a triple spin echo sequence. Once the DANTE RF Pulse checkbox is
enabled, all parameters related to the DANTE RF Pulse appear on the “Special Card”.
A DANTE pulse is formed by the convolution of a rectangular function with a comb
function and multiplied by an amplitude modulation function (i.e. Gaussian):


 t 
t
comb   rect   gauss
 t 
 
2

 
t
ln 2 

Equation A-1

Where t is time, t is the time between each rectangular pulse,  is the duration of each
rectangular pulse and  is the damping coefficient of the Gaussian envelope.
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Since the DANTE pulse is composed of individual hard pulses, the frequency profile of
DANTE pulses is accurately represented by its Fourier Transform:

t combt f  sinc f  

2



2
gauss



ln 2


f 
 

ln 2

Equation A-2

which can be seen to be a comb function multiplied by a sinc function and convolved
with a Gaussian. Therefore, one can control the frequency profile of DANTE pulses by
setting three parameters: t (period), Duration), and (damping coefficient) to express
these parameters in a more practical form: FDP = 1/t, Sinc FWHM = 1.2068/and
Gauss FWHM 
Of course, since the DANTE pulse is a digitized waveform, other parameters, such as the
number of digitization points and the amplitude cut-off for the Gaussian modulation, must
be used for the pulse sequence to construct a specific DANTE pulse.
The following will briefly introduce how the parameters related to this pulse have been
implemented in the MRI scanner user interface.
The “DANTE Modulation” drop menu enables the user to select the shape of the DANTE
RF pulse amplitude modulation: Sinc, Gaussian or none (square). In this thesis all the
experiments were performed using the Gaussian modulation.
The “DANTE AM Cut-off” parameter represents the fraction of maximum amplitude of
the waveform to cut-off the Gaussian waveform, which would otherwise be infinite. In all
of the experiments presented in this thesis, this value was set to 0.05, i.e. 5%, and verified
by phantom experiments.
The “DANTE Passband Width” represents the Full Width Half Maximum of all
passbands, which is represented in parts per million (ppm). A tool tip has been
programmed to display the resulting calculated duration of the DANTE RF pulse in
milliseconds (ms).
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The “DANTE Shift” sets the carrier frequency for the Dante RF pulse. Its value is relative
to the reference frequency determined during the frequency adjustment of the pulse
sequence, presented in parts per million (ppm).
The “DANTE F Domain Period” variable, circled in purple in Figure A-1, represents the
distance in between two successive passbands in the frequency domain. In this thesis, we
used the acronym FDP to represent this quantity. The value is represented in Hertz (s-1).
The use of this parameter is essential to allow the user to excite both the resonance of the
metabolite of interest and a resonance of a reference metabolite simultaneously. The
reference metabolite can be used as a phase reference, amplitude reference or chemical
shift reference in the final spectrum.
The “DANTE Points” parameter represents the number of digitization points of the
DANTE RF pulse waveform.
The “DANTE F-Domain FWHM” represents the Full Width Half Maximum (FWHM) in
Hertz of the intrinsic sinc modulation of the frequency profile of the DANTE pulse. This
is typically set to a very large value so that consecutive passbands have practically the
same amplitude.
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Figure A-1. The “Special Card” illustrating the parameters which
interact with the DANTE RF Pulse.

The optimization parameters:
Several options were added to the special card (circled in orange), such as tools allowing
the run time optimization of selected sequence parameters before the start of the data
acquisition. The calibration of these parameters ensures that the final desired pulse
sequence functionality is achieved and increases the spectral quality and reproducibility.

A. The “Flip Angle Modulation” drop menu:
The user interface provides a drop menu of “FlipAngle (FA) Modulation” that offers the
option of calibrating either the excitation pulse flip angle, the DANTE pulse flip angle, or
the flip angle of both non-DANTE refocusing pulses simultaneously. By placing the
cursor near the user interface entry field, a tool tip displays the current RF pulse and
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gradient crusher parameters, including the flip angle values and the gradient crushers’
amplitude. The starting value of each flip angle is entered manually by the user along
with the incremental step value and the desired number of measurements. Following the
calibration measurement loop, the optimum flip angle value observed can/should be
entered manually prior to the start of the acquisition of the final spectrum. When the
optimization is completed, prior to the start of acquisition of the final data, the “Standard
RF” option must be selected to disable the calibration loop and enable normal looping
(average and measurement loops).
B. The “DANTE Frequency Shift Increment” parameter:
The user interface provides another parameter adjustment loop, “DANTE Freq Shift
INC”, which allows the user to fine tune the adjustment of the frequency offset of the
DANTE RF pulse. This is important since the passbands are so narrow. Misadjustment of
the DANTE frequency offset can result in significant signal loss.
Additionally, the field defines the number of measurements desired and the incremental
step in chemical shift of this adjustment loop.
Following the calibration of the DANTE Frequency shift, the optimum chemical shift
value can/should be entered manually by the user prior to the start of data acquisition.
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Figure A-2. This figure illustrates the modulation parameters including the
drop-down menu for the “Flip Angle Modulation” and the “DANTE Frequency
Shift INC” parameters.
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Appendix B: DANTE Radio Frequency (RF) Pulse
The generation of the DANTE-PRESS sequence is enabled by the implementation of the
DANTE-RF pulse along with its flanking crusher gradients in the pulse sequence as the
second non-slice selective refocusing pulse into a symmetrical PRESS sequence (Version
VB20PSP4, based on modification of Siemens product SVS_SE source code). The
following code/snippet includes the customized process of the implementation of this
“Arbitrary” Gaussian-modulated, frequency-selective, DANTE RF pulse within the
sequence at run time. The DANTE-RF pulse can be prepared with the following
statement and used in the fSEQRun portion of the sequence:
prepArbitrary (pMrProt, pSeqExpo, myRFPulseArray, EffectiveAmplitudeIntegral)
Example code snippet:
/* In Global Declarations */
sSample myRFPulseArray[IRF_MAX_ENVELOPE_ELEMENTS]
/*DANTE waveform vector*/
sRF_PULSE_ARB myRFPulse;
/*DANTE RF Pulse Object*/
fSEQInit (....)
{
....
/* Sequence Special Card Simple DANTE-RF Pulse Variable Declaration */
PARAM ("DANTE RF Pulse", &u_bBoolTestDante, false, "Enables or Disables
the implementation of the Dante RF Pulse and its crusher gradients in
the pulse sequence as the second non-slice selective refocussing
pulse.");
PARAM("DANTE PassbandWidth", "[Hz]", &u_lBandwidth, 0, 100, 1, 15, " The
'DANTE PassbandWidth' representsthe bandwidth of the Dante RF pulse. ");
PARAM("DANTE Points", "[pts]", &dante_pts, 0,8192 , 1, 2560, " The
'DANTE Points' represents the number of points of the Dante RF pulse
waveform.");
PARAM("DANTE AM Cut-off","", &dante_cut, 0, 1, 0.01, 0.05, "The 'DANTE
AM Cut-off' represents the fraction of maximum amplitude of the waveform
to cut-off the Gaussian waveform.");
....
}
fSEQPrep(....)
{
....

113
/* The Gaussian modulated DANTE-RF Pulse is calculated: */
// Set the pulse duration based on the user-requested passband width and
amplitude modulation.
/* Compute DANTE RF pulse duration in seconds for Gaussian */
dante_beta = u_lBandwidth;
/* set passband FWHM for Gaussian modulation */
dante_dur = 4.0/ pi / dante_beta * sqrt(log(2) * 1.0 * log(dante_cut));
p3=dante_dur;
/* puts duration in seconds in shorter variable name for use in long
formulas below */
/* Calculate other DANTE-RF pulse properties */
dante_timeres = dante_dur/dante_pts;
/* calculate square pulse length in number of points */
dante_nsqpts = (int) (dante_tau/dante_timeres);
/* calculate time domain period in number of points */
dante_ndtpts = (int) (dante_deltat/dante_timeres);
/*** Calculate the DANTE-RF shape ***/
// ("Gaussian Pulse ON\n");
t=0;
tinc = dante_dur/(dante_pts-1); /*time increment*/
for (i=0;i<dante_pts;i++)

{

/* set phase to a constant for now */
myRFPulseArray[i].flPha = float (0.);
/* compute within-block index */
k=i % dante_ndtpts;
if (k < dante_nsqpts) {
myRFPulseArray[i].flAbs = float (1.0 * exp(pi * pi / 4.0 /
log(2) * dante_beta * dante_beta * (t-p3/2.0) * (t-p3/2.0)));
} else
{
myRFPulseArray[i].flAbs= float (0.);
}
dRealAmpl += (myRFPulseArray[i]).flAbs *
cos((myRFPulseArray[i]).flPha);
dImagAmpl += (myRFPulseArray[i]).flAbs *
sin((myRFPulseArray[i]).flPha);
t=t+tinc;
} //end of for-loop
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dEffectiveAmplIntegral = sqrt(dRealAmpl*dRealAmpl +
dImagAmpl*dImagAmpl);
} //end of fSEQPrep
fSEQRun(....)
{
myRFPulse.run();
}//end of fSEQRun

Due to the RF hardware limits provided by the Biograph mMR 3.0 T scanner the
maximum duration of an RF pulse cannot exceed 100 ms. Thus, the example code above
allows for the implemention of an arbitrary DANTE-RF pulse with a duration of equal
and less than 100 ms in total (~=>20 Hz). One possible way to implement long duration
RF pulses is to split these pulses into shorter durations with small delays between them.
In order to generate an arbitrary DANTE-RF pulse with duration higher than 100 ms (i.e.
118.54 ms, equivalent to a FWHM equal to 15 Hertz at 3.0 Tesla) and to compensate for
this hardware limitation, two arbitrary Gaussian modulated DANTE-RF pulses must be
implemented each with durations equal and less than 100 ms. This is the approach that
was used in this thesis to achieve DANTE passbands of 15 Hertz.
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Appendix C: Inline Display

The “Inline display” enables the real time monitoring of the measurement loops. The
standard MRS signal post-processing options on the MRI scanner provide basic abilities
to display individual spectral traces as they are being acquired as well as the accumulated
spectrum averaged from all traces acquired at any given time. These traces display only
one spectrum at a time (no option for displaying multiple measurements) and represent
only the signal from the receiver channel with the largest signal (not the channelcombined data).
Programming within the manufacturer’s Image Calculation Environment (ICE) allows the
user to implement custom behaviors for the inline display. The following will provide
examples of the inline display functions implemented as used during calibration loops for
acquisition performed in a phantom (in vitro data). Optimization scans are executed by
using a smaller number of averages (total 1 to 8) to reduce the timeframe of these scans.
The following parameters were optimized and their results were displayed in the inline
display:

(A) The calibration of the flip angle values for the excitation pulse and the
refocusing RF pulses (the calibration of the flip angle value for the DANTE
RF pulse is not demonstrated in the following examples):
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Figure C-3. The inline display illustrates the RF pulse’s flip angle (FA) value,
indicating the production of the maximum signal along with the actual FA
(AFA), transmitter voltage (V), the signal value (S), and highlights the
maximum value with a green label (MaxValue*).

The inline display during fine calibration of the flip angle (FA) for the 90o Excitation
pulse of the D-PRESS sequence using the water unsuppressed signal (1 average, 4
dummy scans) is displayed in Figure C-3. In this example, the excitation pulse voltage of
~370 V produced maximum signal.
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Figure C-4. The inline display illustrates the RF pulse’s flip angle (FA) value,
indicating the production of the maximum signal along with the actual FA (AFA),
transmitter voltage (V), the signal value (S), and highlights the maximum value with
a green label (MaxValue*).
Figure C-4 illustrates the inline display during the simulations fine calibration of the flip
angle (FA) for the two 180o Refocusing RF pulses of the D-PRESS sequence using the
water unsuppressed signal (1 average, 4 dummy scans). This example demonstrates that
for both refocusing pulses the voltage of ~516 V produced maximum signal
The calibration of the flip angle values for the 90o Excitation pulse and the 180o
refocusing pulses of the D-PRESS sequence enables the determination of the optimal flip
angle value, which ensures the reduction in signal loss and the degradation in spectral
quality.
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(B) The calibration of the offset of the DANTE pulse’s carrier frequency.

Figure C-5. The inline display illustrates the DANTE RF pulse’s chemical shift
(CShift) value, the repetition number (REP), the signal value (Signal), and highlights
the maximum value with a green label (MaxValue*).
Fine adjustment of the center frequency of the DANTE pulse using N-AcetylAsparate
Acid as the chemical shift (CS) reference metabolite was obtained from an in vitro
experiment. The inline display during the calibration of the DANTE chemical shift (8
averages, 4 dummy scans) is displayed above (Figure C-5).
In this example, the CS value was incremented in steps of 0.015 ppm. The precise relative
CS value of NAA is ensured and corresponds to 2.01ppm on an absolute ppm scale.
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(C) DANTE chemical shift (CS) calibration for the water resonance:

Figure C-6. The inline display illustrates the calibration of the DANTE chemical
shift for the water peak and highlights the maximum value with a green label
(MaxValue*).

The Water unsuppressed concentration is used as a reference and is acquired with and
without the DANTE pulse. CS fine tuning is used for the DANTE ON water reference.
The inline display demonstrates the channel-combined magnitude spectrum (8 averages, 4
dummy scans (Figure C-6)).
In this example, the CS value of 0.030 ppm produces the maximum signal, as indicated
by the MaxValue* label. The 0.030 ppm CS value was chosen and was entered manually
by the user prior to the start of data acquisition to obtain the DANTE ON water reference
spectrum. This spectrum can be compared with the DANTE OFF water signal to estimate
the magnitude of signal losses, if any, due to the use of the DANTE pulse, yet another
180o pulse with possible flip angle imperfection.
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Appendix D: Gradient Crusher Optimization
In the D-PRESS pulse sequence, every 180o RF pulse was flanked by crusher gradients in
order to selectively produce signal from the triple spin echo. In order to prevent
interference from unwanted coherences (FIDs and spin echo, and stimulated echos), the
area of the crusher gradients of the 180o RF pulses was optimized and modified
accordingly.
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Figure D-7. This figure illustrates how the values for the gradient crusher areas can
be visualized at run-time by the user in response to changes in the pulse sequence
timing and the crusher gradient amplitude allowing for efficient adjustments of
gradient crushing resulting in the elimination of the unwanted coherences
adequately.

By placing a cursor near the user interface entry field, a tool tip displays the calculation of
the total area of the crusher gradients by taking into account the contribution of the
gradient crusher of one, two, three, or four RF pulses, along all three axes. During the
calibration of the gradient crushers, the user can therefore estimate roughly what
parameter values to use in order to effectively remove the unwanted coherences or
quickly identify unwanted coherences with weak gradient crushing.
The following optimized gradient values of the following RF pulses were manually
entered by the user after the optimization procedure was completed:

(RF2): Height of 19 mT/m, duration of 2000 ms
(RF3): Height of 20 mT/m, duration of 2000 ms
(RF4): Height of 18.5 mT/m, duration of 4000 ms.
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Figure D-8. Representative of an in vivo spectrum obtained prior to optimizing the
height of the gradient crushers. Line (A) represents the data in white and the fitting
line in red, lines (B, C and D) illustrate the fitting components of NAA, Cr and Ser in
purple, orange and yellow, respectively, lines (E, F) represent the fitting components
of Gln in blue and Glu in green, respectively. Line (G) represents the residuals in
blue (data minus fit). LW correction factor of 2 Hz was applied. As illustrated the
residuals are considerably large and the template does not fit the data properly.

The in vivo spectrum above was obtained from a healthy participant, with the D-PRESS
sequence using an echo time of 286 ms (DANTE ON at 3.83 ppm, FDP 223 Hz) prior to
gradient crusher optimization. The initial in vivo data obtained contained significant
interference from unwanted coherences, the in vitro template did not fit the data properly,
and the serine concentration obtained was inconsistent from scan to scan.
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Figure D-9. Representative of an in vivo spectrum acquired after the optimizing of
the gradient crushers was performed. Line (A) represents the data in white and the
fitting line in red, lines (B, C and D) illustrate the fitting components of NAA, Cr
and Ser in purple, orange and yellow, respectively, lines (E, F) represent the fitting
components of Gln in blue and Glu in green, respectively. Line (G) represents the
residuals in blue. LW correction factor of 2 Hz was applied. As illustrated the
residuals are negligible and the template fits the data properly.
The spectrum above was acquired with an updated protocol from the same healthy
participant, but using the gradient crusher amplitude values obtained after optimization.
The in vivo data obtained with the new protocol and optimized parameters (gradients)
eliminated unwanted coherences and produced data that could be better modeled by the
metabolite spectral signatures of Cr, Ser, Glu and Gln (notice the flat residuals)
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